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ABSTRACT 
THE DESIGN OF VASCULAR-TARGETED CARRIERS FOR ENHANCED 
INTERACTIONS WITH DISEASED ENDOTHELIUM FROM BLOOD FLOW 
by 
Alex J. Thompson 
Chair: Omolola Eniola-Adefeso 
 
 Particulate carriers proposed for use in vascular-targeting are typically spherical and on 
the nanometer to sub-micron scale.  However, spherical nanoparticles do not efficiently 
marginate, or localize to the cell-free layer (CFL), in blood flow making them sub-optimal as 
vascular-targeted carriers.  Microspheres with diameter ≥ 2 µm are able to efficiently marginate 
in the presence of blood, however may present issues in navigating the vasculature or in adhering 
in the presence of high shear forces.  Here, we investigate how physical design parameters in 
addition to particle size, namely particle shape and density, affect the efficacy of vascular-
targeted carriers (VTC) both in vitro and in vivo.   
 We find that particle shape and density both affect the ability of microparticles to adhere 
to inflamed endothelium from blood flow.  Rod and disk-shaped particles display improved 
adhesion in vitro to endothelium compared to equivalent spheres, provided the aspect ratio is 
xviii 
 
sufficiently high and the equivalent spherical diameter (ESD) is ≥ 1 µm.  These effects were 
confirmed in vivo, as targeted 2 µm ESD rods bound to the aorta of atherosclerotic mice at levels 
~3 times higher than equivalent spheres, while 500 nm rods and spheres displayed minimal 
adhesion.   We also find that particle density affects the ability of nanoparticles (500 nm 
diameter) to target inflamed endothelium.  Silica spheres (2.0 g/cm3) adhered to inflamed 
endothelium in vitro at consistently higher levels than either polystyrene (1.05 g/cm3) or titania 
(3.9 g/cm3) spheres, while titania spheres only display improved adhesion when external forces 
(such as gravity, centrifugal force) also favor adhesion.  Particle density also affected the 
adhesion profile along the aorta of mice with systemic inflammation, with silica spheres 
displaying the most adhesion.  Overall this work shows that particle shape and density are design 
parameters which should be considered to optimize the performance of vascular-targeted 
carriers. 
1 
 
 
 
CHAPTER 1: INTRODUCTION 
 
1.1 Background 
 Systemic administration of therapeutics via the vasculature is an excellent route for drug 
delivery as it provides relatively non-invasive access to essentially anywhere in the body; 
however, traditional free-drug administration is quite inefficient and inherently flawed for a 
number of reasons.  First and foremost, drugs administered in this manner are distributed 
throughout the vasculature, even to healthy tissues, which can cause severe side effects 
particularly for highly potent therapeutics (e.g. chemotherapy), limiting the dosage that can 
safely be administered.  Also, the drug is vulnerable to the body’s innate immune response, 
subjecting the drug to clearance/degradation, limiting the maximum potential effect from the 
dose.  Bolus injections of drugs also present issues in terms of keeping the drug within the 
therapeutic window for an extended period of time, therefore requiring multiple subsequent 
dosages whereas the controlled release of a single drug administration would be more favorable.   
1.1.1 Vascular Targeting 
 Vascular targeting is an emerging drug delivery strategy that holds vast possibilities for 
improving the diagnosis and treatment of many human diseases.1,2  Vascular targeting seeks to 
mitigate the issues associated with free-drug administration and maximize the therapeutic or 
diagnostic effect by providing highly localized, highly site-specific delivery.  Localized delivery 
is desirable in that it can reduce the delivery of potent therapeutics or imaging agents to 
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unwanted areas of the body and maximize delivery to the intended site, minimizing harsh side 
effects and improving imaging/therapeutic effects, while still utilizing the vasculature as the 
route for delivery.  Often, vascular targeting is coupled with particulate drug delivery systems,3 
in which drugs are encapsulated or conjugated to drug delivery “vehicles” on the nanometer or 
micron scale, which can protect the active drug/imaging cargo from premature degradation and 
offers opportunity to engineer the controlled release of therapeutics for sustained or site-specific 
drug delivery.4  The potential for minimizing side effects while also improving the effectiveness 
and longevity of injected therapeutics makes the development of vascular-targeted carriers 
(VTC) an exciting area of research for new disease treatment options.   
1.1.1.1 Active versus Passive Targeting 
 The effectiveness of vascular targeting hinges on the ability of the carrier to navigate the 
vasculature and be able to specifically accumulate in the targeted area of the body.  This can be 
achieved in a variety of ways, however the strategies can typically be defined as either passive or 
active targeting.  Passive targeting relies on the physical characteristics of the carrier and 
physiology of the target environment to achieve localized delivery.  A good example of this is in 
targeting to tumors via the “enhanced permeability and retention” (EPR) effect, in which the 
rapid formation of new vasculature in tumors results in abnormally large fenestrations between 
endothelial cells in these areas (among other abnormalities such as improper lymphatic 
drainage).5,6  Injected carriers in the size range of tens to hundreds of nanometers can diffuse 
through these fenestrations to preferentially accumulate in these tumors, while healthy 
endothelium prevents such carriers from accumulating in healthy tissues, resulting in a 
preferential accumulation of the carrier (and thus the drug/diagnostic) in the tumor tissue.  
Another example of passive targeting would be to use relatively large particles (on the order of 
3 
 
tens of microns in diameter) to specifically accumulate in smaller vessels (such as lung 
capillaries) through which particles cannot physically navigate, or to inject particles which 
readily accumulate in a specific organs.7,8  Active targeting on the other hand, relies on the 
specific interaction between ligands and receptors to produce the desired localized delivery.9  
Often, disease pathologies are accompanied by an overexpression of surface-bound receptors 
either not present or present in low levels on healthy cells.  By coating the surface of the 
vascular-targeted carrier with ligands which specifically interact with these overexpressed 
receptors, a carrier can circulate the vasculature until it “recognizes” the target receptor, allowing 
molecular interaction between ligand and targeted receptor to occur resulting in site-specific 
accumulation of the cargo.  A good example of an active targeting strategy can also be employed 
to target solid tumors.  Tumor vasculature is known to be characterized by rapid new vessel 
formation, or angiogenesis.  Vascular endothelial growth factor, or VEGF, is an endothelial 
expressed receptor which triggers angiogenesis is overexpressed in cancer vasculature for this 
reason.  Vascular-targeted carriers coated with a ligand to VEGF can recognize and adhere to 
overexpressed VEGF, resulting in specific accumulation to tumor vasculature.  Whether utilizing 
passive or active targeting, the optimization of vascular-targeted carrier strategies holds potential 
to vastly improve the treatment and diagnosis of many diseases accessible via the vasculature. 
1.1.2 Opportunities in Vascular-Targeting 
 Active targeting can be applied to treat a plethora of diseases, given that appropriate 
target receptors associated with the disease pathology are identified.    Active targeting has been 
widely investigated for improving the treatment and imaging in cancer.10–12  A variety of 
molecular targets have been identified which are associated with overactive processes present in 
cancer pathology (such as angiogenesis and cell proliferation), as well as targets expressed by 
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specific types of cancers.9,13  Likewise, a wide variety of targeting moieties, including specific 
antibodies, peptides, proteins, and small molecules have been identified for potential use in drug 
targeting.  Multiple antibody-based target cancer therapies have been approved by the FDA14, 
and the further development of drug carrier systems using these targeting molecules hold 
promise in improving therapeutic effects while decreasing side effects.15  
 Active targeting strategies are also of particular interest for improving the treatment and 
early detection of cardiovascular diseases4,16, which remains the leading cause of death in the 
western world.17  Cardiovascular disease is typically caused by atherosclerosis, a narrowing of 
the arteries via a buildup of plaque in the vessel intima.  Atherosclerosis is a chronic 
inflammatory disease, in which chronic inflammation continually elicits an immune response 
locally in specific areas of the vasculature which actually aids in the progression of the disease.  
This chronic inflammation is characterized by the overexpression of inflammatory receptors by 
endothelial cells in the afflicted area.  These inflammatory receptors which include selectins (P 
and E), VCAM-1, ICAM-1, recruit circulating leukocytes from blood flow which transmigrate 
across the endothelium and differentiate into macrophages and eventually foam cells, aiding in 
plaque growth.  However, the inflammatory receptors also provide a convenient platform for 
active targeting.  By coating particles with ligands to these inflammatory markers, localized 
delivery of therapeutics or imaging agents for early detection can be achieved.   
 Regardless of the ligand/receptor pair identified for targeting, a wide variety of carrier 
types can be employed to deliver the intended cargo.  This provides the opportunity for the 
design and engineering of carriers to optimize their ability to successfully target diseased cells or 
tissues.   
5 
 
1.2 Challenges in Vascular-Targeted Carrier Design 
 There are many important obstacles/challenges that must be considered when designing 
VTCs. Carriers administered intravenously face barriers associated with the body’s immune 
system, such as plasma protein absorption, phagocytosis, and clearance from the bloodstream 
which an effective carrier system must be able to overcome to reach the target site.15,18  One 
interesting challenge in carrier design lies in the fact that carriers must be able to efficiently 
“marginate” or localize to the endothelium in order to interact with the target receptors. The 
benefit of a highly specific ligand/receptor targeting system is diminished if the particle never 
interacts with the target because deposition to the target endothelium from blood flow is sub-
optimal.  This issue is of particular concern for targeting diseases such as atherosclerosis which 
affect medium/large blood vessels, where the vessel diameter may be orders of magnitude 
greater than the size of the individual carrier. Further, the interaction between ligands on the 
particle and surface receptors must be strong enough to overcome the shear force and momentum 
on the particle imparted by blood flow in order to result in firm adhesion.  These phenomena 
should be considered when designing vascular-targeted carrier systems.   
1.2.1 Particle Margination 
 It is well known that leukocytes and platelets are able to rapidly and efficiently traffic to 
inflamed endothelium in part because they are able to marginate very effectively, aided by their 
interactions with red blood cells in flow.19–22  Red blood cells tend to move toward the center of 
the vessel in blood flow, forcing white blood cells and platelets to congregate in what is known 
as the “cell-free layer” adjacent to the endothelium.  This combined effect is due in part to the 
difference RBC membrane and leukocyte flexibility, of WBCs, RBC hematocrit, shear, and the 
size of the WBCs and platelets.21,23–26  
6 
 
 This “forced margination” has also been shown to occur for rigid particles, which is of 
interest in vascular-targeted carrier design.  For spherical particles, RBC induced margination 
has been shown to be a function of particle size.  In the presence of RBCs, particles having 
diameters ≥ 2 μm tend to concentrated to the periphery of flow, whereas particles in the 
nanometer or sub-micron diameter range tend to reside in the RBC rich core away from the 
vessel periphery.27–30  This presents a design problem for VTCs, which traditionally have been 
design as spherical particles with diameters in the nanometer to sub-micron range.  This size 
range is advantageous in that these particles can easily navigate microvasculature and experience 
lower shear forces upon adhesion, however the inability to marginate effectively in the presence 
of RBCs limits the potential of targeted nanospheres as drug carriers.   
1.2.2 Particle Adhesion 
Once a targeted carrier has localized to the endothelium, the interactions between 
ligand/receptors must be strong enough to overcome the shear removal forces imparted by blood 
flow.  The magnitude of this shear removal force increases with particle diameter, thus also must 
be considered in the design of VTCs.  Previous work has shown that there exists a “critical shear 
rate” (CSR) for particles in blood flow, above which the momentum/shear removal force is 
sufficient to prevent particles from binding to the endothelium.27 This CSR is particularly 
limiting once particles have diameters on the micron scale, providing an upper size limit 
restriction on VTC design. 
1.2.3 VTC Design Parameters 
To date, particle size has been shown to be an important consideration in designing VTCs. 
Particles which are too large are limited by their ability to safely navigate microvasculature, as 
well as their inability to adhere to endothelium in the presence of high shear forces.  Particles 
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which are too small are limited by their inability to effectively marginate to the endothelium, 
thus making them sub-optimal for vascular targeting. Recently, researchers have found that other 
carrier design parameters in addition to size, such as particle shape, density and 
deformability/rigidity may affect carrier performance.31–33 
1.2.3.1 Particle Shape 
Particle shape has been of particular focus in VTC design, as the advent of new fabrication 
techniques has allowed for the precise design of non-spherical particles.34,35  The use of non-
spherical particles has been of interest for a number of reasons.  Elongated particles in shear flow 
close to a wall have been predicted in silico to experience a lateral drift velocity toward the wall, 
allowing particles to cross streamlines and contact the wall more often than spherical 
particles.36,37  It is hypothesized that this effect could result in increased localization/adhesion of 
non-spherical VTCs compared to traditional spherical particles.  Also, non-spherical particles 
with an elongated shape inherently have advantage over spherical particles in that they can 
present more targeting ligands over a larger contact surface area than equivalent spheres, 
potentially providing a stronger adhesion to withstand shear forces.38  Particles with a 
streamlined shape can also be employed, reducing the shear removal force felt by a particle in 
blood flow.  Early experimental evidence suggests that indeed shape can be used to improve 
adhesion in the presence of shear forces, though these experiments do not take into account 
interactions with RBCs, which are known to have major effects on the margination and adhesion 
of particles and cells in flow.32,39   In addition, shape has been shown to affect the ability of 
phagocytes to successfully engulf particles, which may have an effect on the circulation time of 
an injected VTC.40,41  Thus, one focus of this work is to elucidate the effect that particle shape 
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(coupled with size) has on the targeting affinity of vascular-targeted carriers in blood flow, both 
in vitro and in vivo. 
1.2.3.2 Particle Density 
Another physical parameter to be explored is particle density, which can be altered 
depending on the material makeup of the carrier system being employed.  To date, materials with 
a range of densities have been proposed for use in drug delivery or diagnostics, including 
microbubbles42,43, polymers44–47, liposomes48,49, inorganic particles (titania, gold, iron oxide)50,51, 
blood cells52,53, or combinations of multiple material types54–56. Yet, there is limited 
understanding of the role that density plays in prescribing carrier performance relating to their 
margination and vascular wall adhesion.  Particle density forces seemingly could be regarded as 
negligible in describing particle motion relevant to physiological blood flow, since the 
hydrodynamic forces due to flow (for microparticles) and Brownian forces (for nanoparticles) 
are often orders of magnitude higher than density-dependent body forces such as gravitational 
and centrifugal forces.57,58 However, the distance that a particle must travel in the normal 
direction to the endothelium to initiate contact may also be orders of magnitude shorter than the 
distance the particle travels in the transverse direction. This is particularly true for particles 
already localized to the cell-free layer (CFL) which forms adjacent to the endothelium and has a 
height of only a few micrometers.19  A recent study suggests that particle density negatively 
affects the margination of nanoparticles in microchannel buffer flow, however, the effects of 
particle interactions with RBCs is not taken into account.32 Thus, the second major focus of this 
work is to investigate drug carriers of various particle densities, to elucidate the effect that 
particle density has on the localization and adhesion of targeted particles to inflamed 
endothelium from blood flow, in vitro and in vivo. 
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1.3 Dissertation Focus and Outline 
 The focus of this work is in the design of vascular-targeted carriers, including identifying 
how the physical characteristics of the carrier (such as size, shape, density, and material) can be 
engineered to optimize carrier targeting performance.   
 Chapter 1 gives the introduction to vascular targeting, the challenges and opportunities 
for improved design of vascular-targeted carriers, and the general focus and outline of this 
dissertation. 
 Chapter 2 provides the detailed materials and methods used to gather the experimental 
data described in this dissertation.   
 Chapter 3 provides experimental analysis exploring the effect that particle shape has on 
the ability of vascular-targeted carriers to bind to inflamed endothelium using an in vitro model 
of human vasculature.  The margination and adhesion of spherical and ellipsoidal particles with 
particle sizes ranging from 500 nm equivalent spherical diameter (ESD) and aspect ratios 
ranging from 1 to 11 are explored in a variety of simple and complex blood flow profiles. 
 Chapter 4 provides experimental analysis exploring the effect of particle shape on 
vascular targeting using an in vivo mouse model of atherosclerosis.  This chapter is a 
collaborative project with Katawut Namdee, and the work presented is published in a co-
authored paper in Atherosclerosis journal.59 Dual-targeted spherical and prolate ellipsoidal 
particles with equivalent spherical diameters ranging from 500 nm to 2 µm having aspect ratios 
ranging from 1 (sphere) to 9 are injected into atherosclerotic mice, and the ability to target the 
aorta as well as the biodistribution to major organs is quantified. 
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 Chapter 5 employs an in vitro model of human vasculature to test the effect that particle 
density has on the margination and adhesion to inflamed endothelium in the presence of red 
blood cells.  The targeting ability of polystyrene, silica, and titania spheres with 500 nm diameter 
but with varied densities are investigated. 
 Chapter 6 employs an in vivo mouse model of systemic inflammation to test how 
particles of different material (polystyrene, silica, and titania) and density adhere to inflamed 
aorta and accumulate within major organs. 
 Chapter 7 provides future directions and outlook in the field of vascular-targeted carrier 
design based on the conclusions drawn from the work described in this dissertation as well as the 
current literature. 
  
References 
1. Hajitou, A., Pasqualini, R. & Arap, W. Vascular targeting: Recent advances and 
therapeutic perspectives. Trends Cardiovasc. Med. 16, 80–88 (2006). 
2. Gupta, A. Sen. Nanomedicine approaches in vascular disease: A review. Nanomedicine 
Nanotechnology, Biol. Med. 7, 763–779 (2011). 
3. Kohane, D. S. Microparticles and nanoparticles for drug delivery. Biotechnol. Bioeng. 96, 
203–209 (2007). 
4. Ding, B.-S., Dziubla, T., Shuvaev, V. V, Muro, S. & Muzykantov, V. R. Advanced drug 
delivery systems that target the vascular endothelium. Mol. Interv. 6, 98–112 (2006). 
5. Greish, K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine 
drug targeting. Methods Mol. Biol. 624, 25–37 (2010). 
6. Iyer, A. K., Khaled, G., Fang, J. & Maeda, H. Exploiting the enhanced permeability and 
retention effect for tumor targeting. Drug Discov. Today 11, 812–818 (2006). 
11 
 
7. Cao, F. et al. Lung-targeted delivery system of curcumin loaded gelatin microspheres. 
Drug Deliv. 1–10 (2011). doi:10.3109/10717544.2011.595842 
8. Devarajan, P. V et al. Particle shape: a new design parameter for passive targeting in 
splenotropic drug delivery. J Pharm Sci 99, 2576–2581 (2010). 
9. Byrne, J. D., Betancourt, T. & Brannon-Peppas, L. Active targeting schemes for 
nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60, 1615–1626 (2008). 
10. Béduneau, A., Saulnier, P. & Benoit, J. P. Active targeting of brain tumors using 
nanocarriers. Biomaterials 28, 4947–4967 (2007). 
11. Marcucci, F. & Lefoulon, F. Active targeting with particulate drug carriers in tumor 
therapy: Fundamentals and recent progress. Drug Discov. Today 9, 219–228 (2004). 
12. Choi, C. H. J., Alabi, C. A., Webster, P. & Davis, M. E. Mechanism of active targeting in 
solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 
107, 1235–1240 (2010). 
13. Steichen, S. D., Caldorera-Moore, M. & Peppas, N. A. A review of current nanoparticle 
and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 48, 416–
427 (2013). 
14. Abou-Jawde, R., Choueiri, T., Alemany, C. & Mekhail, T. An overview of targeted 
treatments in cancer. Clin. Ther. 25, 2121–2137 (2003). 
15. Brannon-Peppas, L. & Blanchette, J. O. Nanoparticle and targeted systems for cancer 
therapy. Adv. Drug Deliv. Rev. 64, 206–212 (2012). 
16. Spragg, D. D. et al. Immunotargeting of liposomes to activated vascular endothelial cells: 
a strategy for site-selective delivery in the cardiovascular system. Proc. Natl. Acad. Sci. U. 
S. A. 94, 8795–8800 (1997). 
17. Psarros, C., Lee, R., Margaritis, M. & Antoniades, C. Nanomedicine for the prevention, 
treatment and imaging of atherosclerosis. Maturitas 73, 52–60 (2012). 
18. Sobczynski, D. J. et al. Plasma protein corona modulates the vascular wall interaction of 
drug carriers in a material and donor specific manner. PLoS One 9, e107408 (2014). 
19. Migliorini, C. et al. Red blood cells augment leukocyte rolling in a virtual blood vessel. 
Biophys. J. 83, 1834–1841 (2002). 
20. Munn, L. L. & Dupin, M. M. Blood cell interactions and segregation in flow. Ann. 
Biomed. Eng. 36, 534–544 (2008). 
12 
 
21. Kumar, A. & Graham, M. D. Segregation by membrane rigidity in flowing binary 
suspensions of elastic capsules. Phys. Rev. E - Stat. Nonlinear, Soft Matter Phys. 84, 
(2011). 
22. Kumar, A. & Graham, M. D. Mechanism of margination in confined flows of blood and 
other multicomponent suspensions. Phys. Rev. Lett. 109, (2012). 
23. Zhao, H., Shaqfeh, E. S. G. & Narsimhan, V. Shear-induced particle migration and 
margination in a cellular suspension. Phys. Fluids 24, (2012). 
24. Tateishi, N. Flow dynamics of erythrocytes in microvessels of isolated rabbit mesentery: 
Cell-free layer and flow resistance. J. Biomech. 27, 1119–1125 (1994). 
25. Freund, J. B. Leukocyte margination in a model microvessel. Phys. Fluids 19, (2007). 
26. Kumar, A. & Graham, M. D. Margination and segregation in confined flows of blood and 
other multicomponent suspensions. Soft Matter 8, 10536 (2012). 
27. Charoenphol, P., Huang, R. B. & Eniola-Adefeso, O. Potential role of size and 
hemodynamics in the efficacy of vascular-targeted spherical drug carriers. Biomaterials 
31, 1392–1402 (2010). 
28. Charoenphol, P. et al. Targeting therapeutics to the vascular wall in atherosclerosis-
Carrier size matters. Atherosclerosis 217, 364–370 (2011). 
29. Eckstein, E. C., Tilles, A. W. & Millero  3rd, F. J. Conditions for the occurrence of large 
near-wall excesses of small particles during blood flow. Microvasc Res 36, 31–39 (1988). 
30. Tilles, A. W. & Eckstein, E. C. The near-wall excess of platelet-sized particles in blood 
flow: its dependence on hematocrit and wall shear rate. Microvasc. Res. 33, 211–223 
(1987). 
31. Champion, J. A., Katare, Y. K. & Mitragotri, S. Particle shape: a new design parameter for 
micro- and nanoscale drug delivery carriers. J. Control. Release 121, 3–9 (2007). 
32. Toy, R., Hayden, E., Shoup, C., Baskaran, H. & Karathanasis, E. The effects of particle 
size, density and shape on margination of nanoparticles in microcirculation. 
Nanotechnology 22, 115101 (2011). 
33. Moghimi, S. M., Hunter, a C. & Andresen, T. L. Factors controlling nanoparticle 
pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 
52, 481–503 (2012). 
34. Champion, J. A., Katare, Y. K. & Mitragotri, S. Making polymeric micro- and 
nanoparticles of complex shapes. Proc Natl Acad Sci U S A 104, 11901–11904 (2007). 
13 
 
35. Perry, J. L., Herlihy, K. P., Napier, M. E. & Desimone, J. M. PRINT: A novel platform 
toward shape and size specific nanoparticle theranostics. Acc. Chem. Res. 44, 990–998 
(2011). 
36. Gavze, E. & Shapiro, M. Motion of inertial spheroidal particles in a shear flow near a 
solid wall with special application to aerosol transport in microgravity. J. Fluid Mech. 
371, 59–79 (1998). 
37. Lee, S. Y., Ferrari, M. & Decuzzi, P. Shaping nano-/micro-particles for enhanced vascular 
interaction in laminar flows. Nanotechnology 20, (2009). 
38. Decuzzi, P. & Ferrari, M. The adhesive strength of non-spherical particles mediated by 
specific interactions. Biomaterials 27, 5307–5314 (2006). 
39. Doshi, N. et al. Flow and adhesion of drug carriers in blood vessels depend on their shape: 
A study using model synthetic microvascular networks. J. Control. Release 146, 196–200 
(2010). 
40. Champion, J. A. & Mitragotri, S. Role of target geometry in phagocytosis. Proc Natl Acad 
Sci U S A 103, 4930–4934 (2006). 
41. Champion, J. A. & Mitragotri, S. Shape induced inhibition of phagocytosis of polymer 
particles. Pharm Res 26, 244–249 (2009). 
42. Unger, E., Porter, T., Lindner, J. & Grayburn, P. Cardiovascular drug delivery with 
ultrasound and microbubbles. Adv. Drug Deliv. Rev. 72, 110–126 (2014). 
43. Ting, C. Y. et al. Concurrent blood-brain barrier opening and local drug delivery using 
drug-carrying microbubbles and focused ultrasound for brain glioma treatment. 
Biomaterials 33, 704–712 (2012). 
44. Nance, E. et al. Brain-Penetrating Nanoparticles Improve Paclitaxel Efficacy in Malignant 
Glioma Following Local Administration. ACS Nano (2014). doi:10.1021/nn504210g 
45. Shuvaev, V. V. et al. Endothelial targeting of antibody-decorated polymeric filomicelles. 
ACS Nano 5, 6991–6999 (2011). 
46. Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O. C. 
Targeted polymeric therapeutic nanoparticles: design, development and clinical 
translation. Chem. Soc. Rev. 41, 2971 (2012). 
47. Muro, S. et al. Endothelial targeting of high-affinity multivalent polymer nanocarriers 
directed to intercellular adhesion molecule 1. J. Pharmacol. Exp. Ther. 317, 1161–1169 
(2006). 
14 
 
48. Allen, T. M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. 
Trends Pharmacol. Sci. 15, 215–220 (1994). 
49. Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: From concept to clinical 
applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013). 
50. Liong, M. et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug 
delivery. ACS Nano 2, 889–896 (2008). 
51. Huang, H.-C., Barua, S., Sharma, G., Dey, S. K. & Rege, K. Inorganic nanoparticles for 
cancer imaging and therapy. J. Control. Release 155, 344–57 (2011). 
52. Samokhin, G., Smirnov, M., Muzykantov, V., Domogatsky, S. & Smirnov, V. Effect of 
flow rate and blood cellular elements on the efficiency of red blood cell targeting to 
collagen-coated surfaces. J. Appl. Biochem. 6, 70–75 (1984). 
53. Muzykantov, V. R. Drug delivery by red blood cells: vascular carriers designed by Mother 
Nature. Expert Opin. Drug Deliv. 7, 403–427 (2011). 
54. Park, J. Il et al. Microbubbles loaded with nanoparticles: A route to multiple imaging 
modalities. ACS Nano 4, 6579–6586 (2010). 
55. Anselmo, A. C. & Mitragotri, S. Cell-mediated delivery of nanoparticles: Taking 
advantage of circulatory cells to target nanoparticles. J. Control. Release (2014). 
doi:10.1016/j.jconrel.2014.03.050 
56. Geers, B. et al. Self-assembled liposome-loaded microbubbles: The missing link for safe 
and efficient ultrasound triggered drug-delivery. J. Control. Release 152, 249–256 (2011). 
57. Lee, S. Y., Ferrari, M. & Decuzzi, P. Shaping nano-/micro-particles for enhanced vascular 
interaction in laminar flows. Nanotechnology 20, 495101 (2009). 
58. Jurney, P. et al. The Effect of Nanoparticle Size on Margination and Adhesion Propensity 
in Artificial Micro-Capillaries. Proc. Asme Micro/Nanoscale Heat Mass Transf. Int. Conf. 
2012 109–115 (2012). at <<Go to ISI>://WOS:000324346800015> 
59. Namdee, K. et al. In vivo evaluation of vascular-targeted spheroidal microparticles for 
imaging and drug delivery application in atherosclerosis. Atherosclerosis 237, 279–286 
(2014).  
 
15 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Introduction and Common Materials 
 This section contains the materials and methods used to complete the experimental 
research described in the following four chapters of this dissertation.  Sources of the materials 
and clear procedures are given to allow for reproduction of all results described.  Model 
vascular-targeted carriers are prepared and the propensity to adhere to inflamed endothelium in a 
variety of hemodynamic conditions are investigated, both in vitro using a parallel plate flow 
chamber (PPFC) assay and in vivo using murine models of atherosclerosis or systemic 
inflammation.  The materials (and source) will be listed within the specific subsection for which 
that material was utilized. 
2.1.1 Particles used for Vascular-Targeting 
 Fluoresbrite® YG Carboxylate polystyrene spheres (500 nm, 1 µm, and 2 µm diameter) 
were purchased from Polysciences, Inc. (Warrington, PA).  Fluorescent (green) carboxylated 
silica spheres (500 nm diameter) were purchased from Corpuscular, Inc (Cold Springs, NY).  
Amine-terminated titania spheres were purchased from EPRUI Nanoparticles & Microparticles 
Co Ltd (Nanjing, China).  
2.1.2 Phosphate Buffers 
 Dulbecco’s phosphate buffered saline (with Ca2+ and Mg2+ ions), Dulbecco’s phosphate 
buffered saline (without Ca2+ and Mg2+ ions), sodium dihydrogen phosphate, sodium phosphate 
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dibasic, dextran and bovine serum albumin (BSA) were purchased from Sigma Aldrich (Saint 
Louis, MO).   
 Multiple types of phosphate buffers are used and will be referred to as follows.  50 mM 
PBS is made as 50 mM sodium dihydrogen phosphate, 50 mM sodium phosphate dibasic, and 
0.9% NaOH, and adjusted to pH 7.4.  PBS – 1% BSA refers to 50 mM PBS with 1% w/v BSA 
added.  PBS++1%BSA refers to 1X Dulbecco’s phosphate buffered saline with 1% w/v BSA 
added.  Viscous buffer (VB) refers to PBS++1%BSA with 1.4% w/v dextran added to match the 
viscosity of human plasma.  PBS-\- refers to 1X Dulbecco’s phosphate buffered saline (without 
Ca2+ and Mg2+ ions). 
2.2 Fabrication of Ellipsoidal Particles: Heat Stretching 
 Fluoresbrite® YG Carboxylate polystyrene spheres (500 nm, 1 µm, and 2 µm diameter) 
were purchased from Polysciences, Inc. (Warrington, PA). Poly(vinyl alcohol) (PVA) and 
isopropanol were purchased from Sigma Aldrich (Saint Louis, MO).  Nunc™ OmniTrays™ 
were purchased from Thermo Scientific (Waltham, MA). A previously developed polymer film 
stretching method was used to form prolate (rod-like) and oblate (disk-like) ellipsoidal 
particles.1–3  Polystyrene spheres were suspended in a solution of 10% w/v aqueous PVA and 
cast into a film by pouring into Nunc™ OmniTrays™.  Films were dried on a leveling table 
overnight before being removed from trays for heat stretching.  Ellipsoidal particles were formed 
by stretching films uniaxially using one pair of parallel movable clamps or biaxially using two 
pairs of movable parallel clamps. Clamp mechanisms were housed in customized ovens to allow 
for manipulation of films at high temperature. Films were heated to approximately 150 °C and 
stretched uniaxially to produce prolate ellipsoids (rods) or biaxially to produce oblate ellipsoids 
(disks).  Stretched films were cooled back to room temperature before removing from clamps 
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and dissolving in 30% isopropanol overnight and subsequently washed/centrifuged multiple 
times to ensure minimal residual PVA.  Samples of recovered particle stocks were dried and 
imaged using a Philips XL30 FEG SEM (courtesy of University of Michigan EMAL).  Particle 
dimensions were obtained from SEM images via Metamorph® Software (Molecular Devices, 
LLC).  Rods and disks having equivalent spherical diameters (ESD) of 500 nm, 1 µm, and 2 µm 
and aspect ratios ranging from 2-11, as well as equivalent volume spherical particles were used 
in experiments.  Particle dimensions of ellipsoidal particles will be given in the experimental 
section in which the particles were used.   
2.3 Vascular Targeting: Conjugation with Targeting Ligands 
 Particle surfaces are conjugated with targeting ligands for both PPFC assays and in vivo 
experiments.  In general, functionalized particles (either surface carboxylated or surface 
aminated) are covalently coupled with avidin protein. Then, particles are conjugated with 
biotinylated ligands on the day of the experiment.  After avidin conjugation, the ligand 
conjugation procedure is slightly different between in vitro and in vivo experiments, and as such, 
will be described separately.  
2.3.1 Avidin Conjugation 
 Neutravidin® Biotin Binding Protein (Avidin), NHS-Biotin, and 1-ethyl-3-(-3-
dimethylaminopropyl) carbodiimide hydrochloride (EDAC) were purchased from Thermo 
Scientific (Waltham, MA).  MES hydrate, dimethyl sulfoxide (DMSO), and glycine were 
purchased from Sigma Aldrich (Saint Louis, MO).   
 Carboxylated particles were suspended in 5 mg/mL avidin in 50 mM aqueous MES and 
rotated for 15 min at room temperature.  Then, an equal volume of EDAC solution (75 mg/mL in 
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50 mM aqueous MES) was added to the avidin-particle solution and the solution was adjusted to 
pH of 8.  Particles were rotated for ~20 hours before adding glycine to a final concentration of 
100 mM.  After a 30 min incubation, particles were washed twice and stored with 50 mM PBS at 
4°C until further conjugation.  Aminated particles were suspended in 10 mM NHS-Biotin in 
DMSO and rotated (covered) for 1 hour.  Particles were washed twice with 50 mM PBS, then 
reconstituted in 1 mL of 5 mg/mL avidin in 50 mM PBS and rotated for ~20 hours.  Particles 
were then washed once and reconstituted with 50 mM PBS.  Particles were stored at 4°C until 
further conjugation. 
2.3.2 Ligand Conjugation for In Vitro Flow Assays 
 Biotinylated sialyl Lewis A (sLea) was purchased from Glycotech (Gaithersburg, MD). 
Biotin-FITC conjugate was purchased from Thermo Scientific (Waltham, MA).  Biotinylated 
sialyl Lewis A solution was prepared by dissolving in PBS-1%BSA at a concentration ranging 
between 0.1-10 µg/mL.  The sLea concentration used is pre-determined using flow cytometry 
(described below) to provide the desired sLea site density on the particle surface (#/µm2). The 
number of particles used per conjugation was 1.8 x 107 particles (for 1 and 2 µm ESD particles) 
or 5 x 107 particles (500 nm ESD). Particles were added to 100 µL of sLea solution and rotated 
for 20 mins.  For experiments exploring particle shape (Chapter 3), particles were washed twice 
and stored in 1 mL PBS++-1%BSA at 4°C until used in the experiment.  For experiments 
exploring particle density (Chapter 5), particles were rotated an additional hour with 100 µL 
Biotin-FITC at 5 µg/mL (to aid in post-experiment imaging) before being washed twice and 
stored in PBS++-1%BSA at 4°C.   
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2.3.3 Ligand Conjugation for In Vivo Experiments 
 Biotinylated rat anti-mouse CD106 (aVCAM-1) was purchased from BD Pharmingen 
(San Jose, CA).  A solution of aVCAM-1 was made by dissolving in PBS-1%BSA (5 µg/mL, 
unless otherwise stated).  Avidin-coated particles were added to a solution of sLea and aVCAM 
(equal parts sLea solution and aVCAM solution, 200 µL total) and rotated for 45 min.  For 
experiments exploring particle shape (Chapter 3), particles were washed twice and stored in 1 
mL PBS++-1%BSA at 4°C until used in the experiment.  For experiments exploring particle 
density (Chapter 5), particles were rotated an additional hour with 100 µL Biotin-FITC at 5 
µg/mL to aid in post-experiment imaging before being washed twice and stored in PBS++-
1%BSA at 4°C.   
2.3.4 Quantification of Ligand Site Density 
 Biotin-phycoerythrin conjugate was purchased from Life Technologies (Waltham, MA). 
Biotin-FITC conjugate was purchased from Thermo Scientific (Waltham, MA). Anti-CLA-PE, 
human was purchased from Miltenyi Biotec (San Diego, CA).  Particles coated with sLea were 
incubated with 10 µg/mL anti-CLA-PE in 100 µL total volume for 20 mins.  Isotype controls 
were performed to ensure specificity of staining antibodies.  Particles were washed twice and 
reconstituted in filtered water or PBS-1%BSA before fluorescent intensity (PE) was measured 
with either a BD FACSCalibur® or Attune® Acoustic Focusing Cytometer.  Site densities were 
back calculated by comparing fluorescent intensity with standard calibration beads purchased 
from Bangs Labs (Fishers, IN).  Approximate site densities for particle types used in specific 
experiments are listed in the relevant sections of the text. 
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2.4 Blood Collection and Treatment 
 Blood from human donors was drawn into syringes containing the anticoagulant acetate 
citrate dextrose according to IRB approved protocols and in line with the WMA Declaration of 
Helsinki.  Red blood cells (RBC) were separated by dextran sedimentation for 2 hours and were 
washed once with PBS-/- before storing at 37 °C until use.  All flow assays utilized reconstituted 
blood (RBCs reconstituted in PBS++1%BSA or VB, as specified) at either 30% or 40% 
hematocrit. 
2.5 HUVEC Isolation and Culture 
 Primary human umbilical vein endothelial cells (HUVEC) were obtained from human 
umbilical cords (University of Michigan C.S. Mott Children’s Hospital) according to a 
previously described protocol.4  Briefly, the umbilical veins were filled with a collagenase 
solution for 30 mins, degrading the extracellular matrix to release the HUVEC.  Isolated cells 
were pooled from multiple donors and were grown in culture flasks until confluent.  Subsequent 
passages of HUVEC were either grown in culture flasks or on glass coverslips which were 
coated with porcine gelatin and crosslinked with glutaraldehyde for use in PPFC assays per a 
previously described protocol.5 
2.6 Parallel Plate Flow Chamber  
2.6.1 Experimental Setup 
 A PPFC was purchased from Glycotech (Gaithersburg, MD).  The height and width of 
the flow channel is set by a silicone gasket.  The height and width of the chamber used is 254 µm 
and 1 cm, respectively, unless otherwise specified.  The bottom of the flow chamber is formed 
by a glass coverslip covered with a confluent monolayer of HUVECs.  Laminar flow through the 
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chamber is generated by a programmable syringe pump downstream of the channel, and the 
shear rate at the channel wall is determined using Equation 2.1, where Q is the volumetric flow 
rate, h is the channel height, and w is the channel width.  A range of physiological shear rates are 
investigated, and are specified in the appropriate experimental sections. 
Equation 2.1  Relationship between flow rate, wall shear, and PPFC dimensions 
𝛾𝑤 = 6𝑄ℎ2𝑤 
 Two physiologically relevant pulsatile flow profiles were also investigated via a 
programmable syringe pump; forward flow at alternating low and high shear rates (120-1200 s-1), 
and oscillating forward/reverse flow at high shear (1000 s-1) with a  net forward flow as 
previously described.5,6   
 Also, a step channel was used to simulate regions of recirculation flow, typical of regions 
where atherosclerotic plaques are known to accumulate.6  The step channel has a pre-step 
channel height of 125 µm and a post-step channel height of 500 µm.  A region of recirculating 
flow is created immediately downstream of the step when laminar flow through the channel 
passes over the step.  The recirculating flow region extends to a stagnation, or reattachment, 
point where there is no fluid velocity in the direction parallel to the bottom of the chamber at the 
wall.  Downstream of the reattachment point, flow develops into a 1-dimensional flow profile 
with fluid velocity in the direction parallel to the bottom of the chamber.   
 In the in vitro adhesion assays performed, the flow rate (thus the wall shear rate), flow 
type (laminar, pulsatile, recirculation), hematocrit, and channel orientation all can be varied, and 
are specified in the appropriate experimental sections. 
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2.6.2 Adhesion Assays 
 IL-1β cytokine was purchased from Fitzgerald (Acton, MA).  Confluent HUVEC grown 
on glass coverslips were activated (inflamed) via addition of fresh culture media containing 1 
ng/mL of IL-1β to cells in static for 4 hours.  This treatment induces the upregulation of E-
selectin, to which the targeting ligand on the particle (sLea) binds.  After activation, the coverslip 
is attached to the bottom of the PPFC flow deck.  Targeted particles in reconstituted blood at a 
fixed concentration (5 x 105 #/mL, unless otherwise specified) were then perfused through the 
flow channel at the specified flow conditions for a fixed period of time.  The chamber was 
flushed with PBS++1%BSA at the end of experimental time and the HUVEC monolayer was 
observed using a Nikon TE 2000-S Inverted Microscope.  Adhesion data was captured using a 
Photometric CoolSNAP EZ digital camera with a Sony CCD sensor, and adherent particles were 
quantified using Metamorph® software. 
2.6.3 Localization Assays 
 For localization assays examining the effect of particle size and shape (Chapter 3), the 
same PPFC setup (without HUVEC monolayer) was used to image particles localized to a near-
wall focal plane.  A Leica Inverted SP5X Confocal Microscope (MIL, University of Michigan) 
was used to visualize the localization of fluorescent particles to the CFL from reconstituted blood 
being perfused through a PPFC.  Particle visualization was performed at a focal plane of 2 µm 
height from the bottom of the chamber, unless otherwise specified.  Particles were added to 
reconstituted blood at various concentrations and WSR as specified in the appropriate 
experimental sections.  The localization to the near-wall focal plane for each particle shape/size 
was imaged using Leica Microsystems LAS AF Lite Imaging Software.  The localization of 
differently shaped particles was compared by counting the fluorescent particles seen in each 
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image at the same particle concentration used for adhesion assays.  The localization of micro and 
nanospheres was quantified by mean fluorescence of each image at either 1X (5 x 105 #/mL) or 
5X concentration. 
 For localization assays examining the effect of particle density (Chapter 5), rectangular 
microchannels with the same approximate height used in PPFC assays were utilized.  Sticky-
Slide I 0.2 Luer, sterile rectangular microchannels were purchased from Ibidi LLC (Verone, WI).  
Fluorescent particles were mixed with reconstituted blood and flowed through the microchannel 
at a WSR of 500 s-1.  The microchannel was live-imaged using an Olympus FB 1200 Confocal 
Microscope (compliments of Dr. Greg Thurber, University of Michigan) under 20x 
magnification.  Images were captured of a focal plane within 2 µm into the flow from the top 
surface of the microchannel.  After thresholding the background noise, the “Analyze particles” 
function in ImageJ was used to automatically count the instantaneous number of particles 
localized to the near-wall focal plane. 
2.7 In Vivo Experiments 
 All procedures used for animal experimentation were approved by the University of 
Michigan Committee on Use and Care of Animals (UCUCA) and are in compliance with the 
guidelines for the “Care and Use of Laboratory Animals” set by the University, State, and 
Federal regulations.  A murine model of atherosclerosis (ApoE -/-) was employed to examine the 
plaque targeting of spherical and rod-shaped targeted particles (Chapter 4).  A wild-type mouse 
model of systemic inflammation was employed to examine the inflammation targeting ability of 
particles with different density (Chapter 6).  The materials and methods are described separately 
as follows.  
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2.7.1 Apo E -/- Murine Model 
 Twenty-five homozygous ApoE-/- mice and twenty-five wild-type mice at 8-10 weeks of 
age were purchased from Jackson Laboratories (Bar Harbor, ME).  Mice were fed a normal diet 
for 20 weeks.  Mice with an average weight of 28 g were randomly assigned into five groups of 
five animals, and dual-targeted particles were administered via a 200 µL bolus injection into the 
tail vein at a dosage of 20 x 106 particles in phosphate buffered saline per mouse.  The post 
injection protocol is described further in section 2.7.3. 
2.7.2 Systemic Inflammation Model 
 Mouse TNF-α cytokine was purchased from BD Pharmingen (San Jose, CA).  Twenty-
four wild-type male mice at 20 weeks of age were purchased from Jackson Laboratories (Bar 
Harbor, ME).  Mice were assigned to three groups of five animals (dual-targeted) and three 
groups of three animals (IgG controls), and each mice was injected via tail-vein with Mouse 
TNF-α cytokine at a concentration of 10 ng/mL in 300 µL PBS to induce inflammation of the 
murine vasculature. Twenty-four hours after injection of TNF- α, particles were injected via tail-
vein at a dosage of 40x106 particles per mouse in 200 µL of PBS. The post injection protocol is 
described further in section 2.7.3. 
2.7.3 In Vivo Experimental Protocol 
 30 min after injection, mice were anaesthetized with 100 µL of a mixture of 35% 
ketamine and 5% xylazine in PBS, and additional anesthesia was administered as necessary.  
Blood was drawn via cardiac puncture from the left ventricle using a heparin-coated syringe.  
Then, the right atrium was nicked and the vasculature was perfused with ice-cold PBS by 
injection into the puncture site at the apex of the left ventricle.  The lung, liver, spleen, and 
kidney were harvested and snap-frozen in liquid nitrogen.  Consequently, the heart and aorta 
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were perfused again with ice-cold 4% paraformaldehyde (PFA) in PBS at pH 7.5.  Whole mice 
were preserved in 4% PFA until aorta isolation.  The aorta were excised from the aortic arch to 
the iliac branches, including the renal branches and celiac branch, and kept in 4% PFA in PBS.  
 Aortae were excised into segments along the full length including the aortic arch, 
abdominal branches, and iliac branches.  Aortic segments were bisected and mounted open en 
face on glass slides with 4% PFA, and coverslips were sealed using nail polish agent.  Aorta 
were imaged using a Nikon TE 2000-S Inverted Microscope and an attached Photometric 
CoolSNAP EZ digital camera with a Sony CCD sensor (Chapter 4) or an Olympus FB 1200 
Confocal Microscope (Chapter 6) under 20x, 40x, or 60x magnification.  En face images were 
quantified by counting the number of adherent particles to the aorta.  For each group of mice, the 
number of adherent particles along the entire aorta was averaged.  Particle adhesion was also 
normalized to the area of each section, to give an adhesion density per section of aorta. 
   Particle biodistribution in major organs was also quantified.  Multiple samples from 
each organ were weighed and homogenized in 1 mL of PBS++.  The concentration of particles in 
each homogenized solution was quantified using a hemocytometer.  For the lungs and liver, a 
portion of the organ was harvested and analyzed for particle accumulation.  For lungs, a portion 
of the left lobe was used, and for the liver, a portion of the left lateral lobe was used.  Whole 
organs were used to quantify particle accumulation in the kidney and spleen.  Particle 
accumulation is reported as % injected dose/gram organ (%ID/g).   
2.8 Data Analysis  
 Data for in vitro adhesion experiments is quantified as the number of adherent particles 
per mm2 of endothelium.  Ten fields of view (20x magnification) were imaged, and the average 
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number of adherent particles per field of view is divided by the field of view area. Adhesion 
density following recirculation flow experiments is quantified at 100 µm intervals downstream 
from the step, so the adhesion is divided by the appropriate area of a 100 µm wide lateral region 
at 20x magnification. Standard error bars are plotted and significant differences are analyzed via 
a one-way ANOVA with Tukey’s post-test or student t test, with a p value < 0.05 considered 
statistically significant, unless otherwise stated.   
 Data for localization experiments was quantified in one of two ways.  For localization 
experiments comparing 500 nm and 2 µm ESD spheres (Chapter 3), the mean fluorescence per 
image is calculated and normalized to the mean fluorescence at 1x concentration.  For 
localization experiments comparing spheres and ellipsoids (Chapter 3) or particles of different 
density (Chapter 6), an instantaneous particle localization is quantified as the average number of 
particles visible in the field of view divided by the field of view area.  Standard error bars are 
plotted and significant differences are analyzed via a one-way ANOVA with Tukey’s post-test or 
student t test, with a p value < 0.05 considered statistically significant, unless otherwise stated.   
 Aorta adhesion data for in vivo experiments is reported as average number of particles 
adherent to the whole aorta, as well as the average particle adhesion to each aortic section.  Also, 
adhesion is normalized to the area of each aortic section to give the particle adhesion density.  
For experiments comparing particles of different shape (Chapter 4), adhesion is normalized to 
the adhesion of 500 nm spheres.  Standard error bars are plotted and significant differences are 
analyzed via a one-way ANOVA with Tukey’s post-test or student t test, with a p value < 0.05 
considered statistically significant, unless otherwise stated.   
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 Biodistribution data for in vivo experiments is reported as % injected dose/gram organ 
(%ID/g).  Standard error bars are plotted and significant differences are analyzed via a one-way 
ANOVA with Tukey’s post-test or student t test, with a p value < 0.05 considered statistically 
significant, unless otherwise stated.   
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CHAPTER 3: THE MARGINATION PROPENSITY OF ELLIPSOIDAL 
MICRO/NANOPARTICLES TO THE ENDOTHELIUM IN HUMAN 
BLOOD FLOW 
 
The majority of the work in this chapter is published as AJ Thompson, EM Mastria, and O Eniola-
Adefeso. The margination propensity of ellipsoidal micro/nanoparticles to the endothelium in human 
blood flow.  Biomaterials 34 (23), 5863-5871 (2013). 
 
ABSTRACT 
 Particle shape is becoming increasingly recognized as an important parameter for the 
development of vascular-targeted carriers (VTC) for disease treatment and diagnosis.  However, 
limited research exists that investigates how particle shape coupled with hemodynamics affects 
VTC margination (localization and adhesion).  In this study, we investigate the effects of particle 
shape parameters (volume, aspect ratio, axis length) on the margination efficacy of targeted 
spheres, prolate ellipsoids, and oblate ellipsoids in an inflamed endothelial wall from human 
blood flow in an in vitro model of human vasculature.  Overall, particles with 2 μm equivalent 
spherical diameters (ESD) display higher margination than particles with either 1 μm or 500 nm 
ESDs.  Interestingly, rod-shaped microparticles (1 μm or 2 μm ESD) with high aspect ratios 
display significantly improved margination compared to spheres of equal volume, particularly 
under high shear rates and disturbed flow profiles.  Nanorods (500 nm ESD), even with high 
aspect ratio, do not display enhanced margination compared to that of equivalent spheres, which 
suggests that nanorods, like nanospheres, display minimal margination due to their inability to 
effectively localize to the vessel wall in the presence of red blood cells (RBC). 
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3.1  Introduction 
 Vascular-targeted carriers (VTC) offer unique opportunities to improve disease diagnosis 
and treatment by providing highly localized delivery of therapeutics/imaging agents.  Regardless 
of the carrier type (e.g. polymeric, liposomes, dendrimers, micelles, etc) the typical geometry for 
a VTC is spherical with diameters on the nanometer scale. However, recent publications have 
shown that nanospheres may be suboptimal for targeting diseases affecting larger vessels with 
bulk blood flow, such as atherosclerosis.1,2  In bulk blood flow, red blood cells (RBC) tend to 
move to the center of flow, resulting in a RBC core that forces leukocytes and platelets to 
concentrate into the red blood “cell free layer” (CFL) adjacent to the vascular wall.  This 
enhanced concentration at the wall, i.e. “near-wall excess”, then allows for these cells to 
optimally interact with the endothelium despite large vessel diameters.  Microspheres (2-10 μm 
diameters) can also take advantage of the near-wall excess mechanism1–4, allowing for their 
efficient margination (localization and adhesion) to the endothelium from bulk blood flow.  
Nanospheres, however, are not similarly displaced to the CFL, and thus exhibit minimal 
margination from bulk blood flow.1–5  
 Therefore, one major challenge in targeting atherosclerosis is in designing carriers that 
have the capacity to localize to and have a high affinity for binding to the vascular wall from 
bulk blood flow.  Recent published works have suggested that deviating from the typical 
spherical shape of VTCs could potentially improve VTC performance.  Specifically, 
macrophages are reported to be less efficient at engulfing elongated particles of sufficient 
volume than spheres, which could translate to reduced clearance and lower accumulation in non-
targeted organs.6,7  Indeed, non-spherical microparticles of similar volume have been shown to 
have different in vivo biodistribution profiles in tumor-bearing mice.8  Drug-loaded filamentous 
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micelles have also been shown to persist in circulation for much longer than spherical micelles in 
mice9, and ICAM-1 targeted elliptical disks were shown to have a longer circulation half-life and 
a better targeting specificity than their spherical counterparts.10  Theoretical works have also 
predicted that ellipsoidal particles display a preferential lateral drift in shear flow near a wall 
(analogous to the CFL).11,12  Also, disk-shaped particles are predicted to better adhere to 
endothelial cells in the presence of flow-induced shear stress, due to both a higher contact 
surface with the endothelium and a streamlined shape.13  Recent experimental works have also 
demonstrated that particle elongation can increase particle adhesion to protein-coated surfaces in 
microchannels; however these works were done with particles in low shear buffer flows and thus 
do not provide indication as to whether these particles can better localize to the CFL from the 
RBC core than spheres.14,15  Thus, it largely remains unclear how particle shape affects 
margination in human blood flow, and in conditions relevant to targeting the endothelium in 
blood vessels with bulk blood flows.   
 This study seeks to evaluate the efficiency of rod-shaped and disk-shaped, relative to 
spherical, model VTCs in marginating to the vascular wall in the presence of RBCs via parallel 
plate flow chamber (PPFC) adhesion assays, with the central goal of identifying particle shape 
parameters (volume, aspect ratio, major/minor axis length), if any, that are paramount in 
determining the capacity for VTCs to readily marginate in physiological human blood flow 
conditions.  Pulsatile and recirculation blood flow patterns were used in adhesion assays for 
relevance in large arteries and areas of sudden expansion within these arteries, respectively, that 
are typically afflicted with atherosclerosis.  Steady laminar blood flow was explored for their 
relevance in small arteries (i.e. arterioles) that are important in cancer and some cardiovascular 
diseases, including arteriolosclerosis and specific types of vasculitis. 
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3.2 Results 
 Prolate ellipsoids (rods) having ESD of 2 µm, 1 µm, and 500 nm were used with aspect 
ratios ranging from 2 to 11.  The dimensions of the particles used in this study are given in Table 
3.1, where rods are denoted by their aspect ratios (AR) – the ratio of the major axis length to the 
minor axis length.   
Table 3.1  Dimensions for spherical and rod-shaped particles used in adhesion experiments 
(ESD=equivalent spherical diameter) 
 
 
3.2.1 Particle adhesion in laminar blood flow 
 Figure 3.1 shows the adhesion of spheres and rods with an equivalent spherical diameter 
(ESD) of 2 μm to an activated HUVEC monolayer from laminar blood flow of reconstituted 
human blood at 30% hematocrit (Hct - % RBC by volume) in a PPFC.  At a wall shear rate 
(WSR) of 200 s-1, there was no difference in the adhesion of particles between the different 
shapes.  At 500 s-1, all spheres and rods with aspect ratio (AR – the ratio of the major axis length 
Particle Shape ESD [μm] Aspect Ratio
Major Axis 
[μm]
Sphere 1.00 2.07
AR-2 2.11 3.39
AR-4 4.03 5.21
AR-9 9.09 8.97
Sphere 1.00 1.01
AR-2 1.98 1.61
AR-4 4.17 2.76
AR-11 11.23 5.90
Sphere 1.00 0.52
AR-2 2.14 0.85
AR-4 4.50 1.40
AR-10 10.15 2.41
0.52
2.07
1.01
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to the minor axis length) ≤ 4 displayed the same level of adhesion, while the adhesion density of 
rods with AR of 9 was 31% higher than that of equivalent spheres.  At the highest WSR of 1000 
s-1, the adhesion density of AR ≤ 4 was either the same or slightly higher than spheres; however, 
the adhesion density of AR-9 rods was 121% higher compared to spheres.  Overall, as the WSR 
increased, the adhesion density for each particle type also increased – likely due to the increased 
number of particles fed through the chamber at higher shear rates for a fixed experiment time.  
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Figure 3.1  Adhesion density (A) and flux-normalized adhesion (B) of sLea-coated spheres and 
rods (2 μm ESD) to activated ECs from 30% RBCs in buffer after 3 min of steady flow through a 
PPFC.  A fixed sLea density of 970 ± 40 sites·μm-2 is used for all particles.  Flux-normalized 
adhesion is achieved by dividing the particle adhesion density by the absolute number of 
particles fed through the PPFC after 3 min of flow.  Particle concentration = 5 x 105 #/mL blood. 
* = not significant (p > 0.01) compared to adhesion of the same particle at the immediately lower 
WSR and # = not significant (p > 0.01) compared to adhesion of spheres at the same WSR via 
one-way ANOVA with Tukey post-test, n ≥ 3.  
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 To better understand how efficiently particles adhere under different shear conditions, the 
adhesion data was normalized for the increased particle flux with increasing shear rates by 
dividing the adhesion density by the total number of particles that passed through the flow 
chamber.  From the normalized data (Figure 3.1B), it is apparent that the binding efficiency of 
spheres and rods with AR ≤ 4 decreased with increasing WSR.  However, the AR-9 rods 
displayed the same binding efficiency over all shear rates despite the higher shear forces present 
at higher WSRs.  Similar results were obtained for AR-9 rods when adhesion efficiency was 
evaluated with assays having the total amount of particles fed into the flow chamber fixed 
between low and high WSR (Figure 3.2A), e.g. the concentration of particles fed at 1000 s-1 was 
5 times lower than the concentration fed at 200 s-1 for a fixed experiment time of 3 min.   
 Particle binding assays were also performed with particles having a fixed total number of 
sLea copies to see if the maintained binding efficiency shown for AR-9 rods compared to spheres 
is simply a result of a higher number of ligand copies on rods for experiments done with a fixed 
ligand density as in Figure 3.1B (spheres and rods have a fixed sLea density of ~1000 sites/μm2, 
thus rods have a higher number of total targeting ligand copies available for binding).  As shown 
in Figure 3.2B, with all particles having about 14,000 ± 1000 (SE) sLea copies on their surface, 
the adhesion for the AR-9 rods (now at ~600 sLea sites/μm2) was still higher than that of spheres 
(~1000 sLea sites/μm2) at both 500 and 1000 s-1 WSR.  Also, the adhesion of AR-9 rods 
increased as the WSR is increased from 500 to 1000 s-1 – however the level of adhesion does not 
quite double (as was the case for the fixed sLea density assays shown in Figure 3.1). 
 To determine if rods exhibit enhanced localization to the CFL from the RBC core, the 
localization of spheres, AR-4 rods, and AR-9 rods to the CFL was visualized using confocal 
microscopy at the same 1000 s-1 condition used in the laminar adhesion assay.  Images were 
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taken to show the number of particles localized to a near-wall region 2 μm away from the step at 
any instant. No significant difference in the average number of particles localized to the CFL was 
observed between spheres and rods with 2 μm ESD (Figure 3.3).   
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Figure 3.2  Adhesion density of spheres and AR-9 rods with ESD of 2 μm from 30% RBC in 
buffer to activated HUVEC following 3 min of steady flow through a PPFC with either (A) a 
fixed particle flux or (B) a fixed number of sLea sites on all particles at a fixed particle 
concentration.  The fixed particle flux condition was achieved by feeding particles into the PPFC 
at a 5x lower concentration at 1000 s-1 than at 200 s-1.  Particles used in the fixed sLea number 
experiment were coated with a total of 14,000 ± 1000 sLea/particle.  * = not significant (p > 0.01) 
compared to adhesion of the same particle at the immediately lower WSR and # = not significant  
(p > 0.01) compared to adhesion of spheres at the same WSR via one-way ANOVA with Tukey 
post-test, n ≥ 3.  
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Figure 3.3  Number of particles localized to the CFL from 30% Hct RBC in buffer flow in a 
PPFC at a WSR of 1000s-1 normalized to the square area of each confocal image analyzed.  ns = 
p > 0.01 
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 Next, the adhesion density of spheres and rods with 1 μm ESD to activated HUVEC was 
evaluated in laminar RBC flows at 30% Hct (Figure 3.4).  The adhesion density for AR-11 rods 
was significantly higher than that of equivalent spheres at all WSRs and was more pronounced 
with increasing WSRs.  Also, the adhesion density for AR-4 rods was higher relative to spheres 
only at the 1000 s-1 WSR while AR-2 rods displayed similar adhesion levels as their equivalent 
spheres at all WSRs evaluated.  Similar to particles with 2 μm ESD, when adhesion was 
normalized to particle flux, there was a significant decrease in the binding efficiency of 1 μm 
ESD spheres, AR-2 rods, and AR-4.  The adhesion efficiency of AR-11 rods only slightly 
decreased (by ~25%) for the WSR increase from 500 s-1 to 1000 s-1 (data not shown). 
 In light of the adhesion trend shown in Figure 3.4A, we sought to determine if an increase 
in blood Hct would affect the adhesion trend for 1 μm ESD rods and spheres by conducting flow 
assays with a 40% Hct (Figure 3.4B) – reducing the height of the CFL and providing a better 
protective force normal to the HUVEC monolayer for particles near the vessel wall.16  At 40% 
Hct, the adhesion level of AR-11 rods was significantly higher than equivalent spheres only at 
500 and 1000 s-1, whereas adhesion was higher than spheres at all WSR in 30% RBC flow. There 
was also no significant difference in the binding between spheres and AR-2 rods at any WSR 
examined in 40% RBC flow while AR-4 rods displayed higher binding than spheres only at the 
WSR of 1000 s-1.  
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Figure 3.4  Adhesion density of spheres and rods (1 µm ESD) coated with a fixed sLea site 
density (970 ± 40 sites/µm2) to activated ECs from 30% (A) and 40% (B) RBC in buffer 
following 3 min of steady flow at various shear rates through a PPFC.  Particle concentration = 5 
x 105 #/mL blood.  * = not significant (p > 0.01) compared to adhesion of the same particle at the 
immediately lower WSR and # = not significant (p > 0.01) compared to adhesion of spheres at 
the same WSR via one-way ANOVA, n ≥ 3. 
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Again, the increases in the binding of AR-11 rods relative to spheres was not solely a 
result of rods having more total copies of sLea, since assays performed at 40% Hct with a fixed 
total ligand number show that the adhesion of AR-11 rods remains significantly higher than that 
of spheres at both 500 s-1 and 1000 s-1 (Figure 3.5A).  Also, localization of spheres and AR-11 
rods to the CFL was visualized via confocal microscopy at the same 1000 s-1 WSR condition 
(30% Hct) used in the laminar adhesion assay shown in Figure 3.4A.  Interestingly, the 
localization data indicated that the AR-11 rods with 1 μm ESD localized to the CFL at levels 
~25% lower than equivalent spheres (Figure 3.5B), despite displaying adhesion levels greater 
than equivalent spheres.  Also, as expected, the 1 μm ESD spheres localized to the CFL at levels 
~42% less than 2 μm spheres. 
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Figure 3.5  (A) Particle adhesion of spheres and aspect ratio (AR) 11 rods with 1 µm ESD from 
30% RBC in buffer flow to activated ECs following a 3 min of steady flow through a PPFC with 
a fixed sLea number on all particles at a fixed particle concentration.  Particles used in the fixed 
sLea number condition were coated with ~3100 sLea  sites/particle.  (B) Number of particles 
localized to the CFL from 30% Hct RBC in buffer flow in a PPFC at a WSR of 1000s-1 
normalized to the square area of each confocal image analyzed.  * = not significant (p > 0.01) 
compared to adhesion of same particle at the immediately lower WSR and # = not significant (p 
> 0.01) compared to adhesion of spheres at the same WSR via one-way ANOVA, n ≥ 3. 
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 Figure 3.6 shows the adhesion of spheres and rods with 500 nm ESD from 40% RBC in 
buffer after 3 min of laminar flow in a PPFC.  Consistent with previous experimental work1,2,5, 
the adhesion levels of nanoparticles were much lower than that of microparticles.  Increasing the 
WSR did not result in a significant difference in the adhesion for any of the particle shapes.  
More importantly, the adhesion density of rods with 500 nm ESD was equal or lower than that of 
their equivalent spheres, regardless of aspect ratio.  Indeed, the normalized data shows that the 
rods bound significantly less efficiently than spheres as the channel WSR increased (Figure 
3.6B). 
 We see that although particle shape can improve particle adhesion, particle size is still an 
important factor in determining overall targeting, due to the ability or inability of particles to 
preferentially localize to the CFL in the presence of red blood cells.  We investigated this RBC-
enhanced localization effect with fluorescent 2 µm and 500 nm diameter spheres by imaging a 
near-wall focal plane in a PPFC using a confocal microscope and measuring the average 
fluorescent intensity of each image.  Figure 3.7 shows the response in near-wall fluorescence 
caused by a 5X increase in particle concentration fed.  In line with previous research, we see that 
in the presence of RBCs at a physiological Hct, increasing the particle concentration of 2 µm 
diameter spheres by 5X resulted in ~7.5X increase in fluorescence intensity.  The same 
experiment but with 500 nm ESD only results in a ~3X increase in near-wall fluorescence.  Also, 
increasing the 2 µm sphere concentration by 5X in blood results in a greater increase in near-wall 
fluorescence compared to in buffer flow, but increasing the 500 nm sphere concentration by 5X 
results in a greater increase in fluorescence in buffer flow rather than blood flow. This reinforces 
the importance of particle size in determining margination in the presence of RBCs, and is likely 
the reason non-spherical nanoparticles also show minimal binding in blood.  
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Figure 3.6  Adhesion density (A) and flux-normalized adhesion (B) of spheres and rods (500 nm 
ESD) coated with a fixed sLea density (970 ± 40 sites/µm2) to activated ECs from 40% RBC in 
buffer following 3 min of steady flow at various shear rates through a PPFC.  Particle 
concentration = 5 x 105 #/mL blood.  * = not significant (p > 0.01) compared to adhesion of same 
particle at the immediately lower WSR and # = not significant (p > 0.01) compared to adhesion 
of spheres at the same WSR via one-way ANOVA, n ≥ 3. 
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Figure 3.7  The ratio of fluorescence intensity of nanospheres (top) and microspheres (bottom) in 
the near-wall focal plane for the 5x105 (1X) relative to the 2.5x106 (5X) particles/mL feed 
concentrations in RBC in buffer flow at 30% Hct and in PBS++1%BSA flow at a WSR of 200 s-
1  in a PPFC.5 
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 Also of interest is whether disk shaped particles on the sub-micron or nano range would 
show improved adhesion compared to spheres.  The disks were also prepared via heat-stretching, 
except they were stretched biaxially rather than uniaxially.  The dimensions of the disks used in 
these experiments are listed in Table 3.2 (AR is calculated as the average of the widths divided 
by the thickness).  Figure 3.8 shows the adhesion of disk shaped targeted particles with 1 μm and 
500 nm ESD compared to spheres and rods of equivalent volume, while Figure 3.9 shows the 
adhesion of disks with 2 μm ESD compared to equivalent spheres.  1 μm ESD disks show 
increased adhesion compared to equivalent spheres, though no different from the 1 μm ESD rods 
discussed previously (AR-11).  Also, 500 nm ESD disks did not adhere significantly higher than 
equivalent spheres.  Disks with 2 μm ESD display a similar improvement in adhesion compared 
to equivalent spheres as was shown for high AR rod-shaped particles.   
Table 3.2  Dimensions for disk-shaped particles used in adhesion experiments 
 
  
Particle Shape ESD [μm]
Width 1 
[μm] 
Width 2 
[μm] 
Thickness 
[μm] Aspect Ratio
Disk 0.53 0.90 0.87 0.10 9.2
Disk 1.01 1.71 1.36 0.23 7.1
Disk 1.83 2.80 2.47 0.45 6.1
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Figure 3.8  Adhesion density of targeted spheres, rods, and disks (1 µm and 500 nm ESD) to 
activated ECs from 40% RBC in buffer following 3 min of steady flow at a WSR of 500 s-1.  
Particle concentration = 5 x 105 #/mL blood.  ns = not significant (p > 0.01) 
  
47 
 
 
Figure 3.9  Adhesion density of targeted spheres and disks (2 µm ESD) to activated ECs from 
40% RBC in plasma following 3 min of steady flow at varied WSR.  Particle concentration = 5 x 
105 #/mL blood.  * indicates p < 0.01 comparing adhesion of spheres and disks at the same shear 
rate. 
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3.2.2 Particle adhesion in pulsatile blood flow 
 Particle adhesion was examined from two different pulsatile blood flow profiles at 40% 
Hct – (1) a forward flow at alternating low and high shear rates (120 s-1 – 1200 s-1) and (2) 
alternating forward/reverse flow at high shear (1000 s-1) with a net forward flow.2  As shown in 
Figure 3.10, AR-9 rods with 2 μm ESD displayed over 130% higher adhesion compared to their 
equivalent spheres in both pulsatile profiles.  There was no difference between the adhesion of 2 
μm spheres and AR-2 rods, and a slightly higher adhesion level for AR-4 rods compared to 
spheres was observed only in the alternating low/high shear flow (Figure 3.10A).  The adhesion 
trend seen for 1 μm ESD particles in pulsatile flow was similar to the trend seen for laminar 
flow, in which there was no difference in adhesion between spheres and rods of AR-2 or AR-4, 
but AR-11 rods adhere to HUVEC at ~140% higher levels than equivalent spheres in both 
pulsatile profiles.  As with laminar flow assays, rods with 500 nm ESD in pulsatile flow showed 
either the same or slightly lower adhesion levels than 500 nm diameter spheres.  Overall, 
adhesion of particles with 2 μm ESD was significantly higher than particles with 500 nm and 1 
μm ESDs of similar shape in both pulsatile flow profiles explored – up to ~2500% for the longest 
AR rods.  
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Figure 3.10  Adhesion of spheres and rods to activated ECs from (A) alternating low/high shear 
forward flow and (B) oscillating high shear flow profiles from 40% RBC in buffer at a particle 
concentration of 5 x 105 #/mL.  Experiment times corresponded to 3 min of net forward flow 
(Total experiment times were 3 min for low/high flow and 9 min for oscillating flow).  # = not 
significant (p > 0.01) compared to adhesion of spheres at the same size (ESD) via one-way 
ANOVA, n ≥3. 
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3.2.3 Particle adhesion in recirculation blood flow 
 A step channel was used to examine particle adhesion from a recirculating flow profile.  
Figure 3.11 shows particle adhesion densities in the flow recirculation region, stagnation point, 
and far downstream of the stagnation point for particles having ESD of 2 μm.  At 200 s-1 of shear 
(set to channel height downstream of flow expansion), adhesion at areas within the recirculation 
zone (see methods section) for 2 μm ESD particles showed no dependence on particle shape.  In 
the disturbed flow region downstream of the stagnation point, only the adhesion density of AR-9 
rods was higher than that of equivalent spheres (86% higher).  Far downstream from the 
stagnation point where laminar flow is reestablished, the adhesion of AR-9 rods is also higher 
than equivalent spheres, though only 46% higher.  With a downstream WSR of 500 s-1, the 
adhesion density of AR-9 rods both upstream and downstream of the stagnation point and in the 
far downstream region was ~85% higher than that of equivalent spheres.  Shorter (AR-2 and AR-
4) rods displayed either slightly lower or no difference in their adhesion compared to spheres at 
both shear rates.  Also, increasing the particle flux by a factor of 5/2 via higher WSR (comparing 
500 s-1 versus 200 s-1 in Figure 3.11) only increased the far downstream adhesion of spheres by 
85%, while the same increase in flux of AR-9 rods resulted in 140% higher adhesion – indicating 
either a better transport to the vessel wall or an improved capacity for adhesion. 
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Figure 3.11  Adhesion of spheres and rods with 2 µm ESD to activated ECs from 40% RBC in 
buffer at a fixed particle concentration of 5 x 105 #/mL.  Experiment was performed in a flow 
channel with a sudden expansion which causes recirculation flow to occur.  Data is plotted as a 
function of the distance downstream of the sudden expansion.  # = not significant (p > 0.01) 
compared to adhesion of spheres at the same WSR via one-way ANOVA, n ≥ 3. 
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 For 1 μm ESD particles, only AR-11 rods showed significantly higher adhesion than 
equivalent spheres in the region beyond the stagnation point for both downstream WSRs of 200 
and 500 s-1 (Figure 3.12).  However, note that even with recirculation flow, which could 
potentially cause redistribution of particles toward the vessel wall – the adhesion density of 1 μm 
ESD for all shapes was relatively low  compared to particles with 2 μm ESDs.   
 For 500 nm ESD particles, similar to observation in laminar and pulsatile flows, adhesion 
in recirculating flow was minimal with no apparent improvement in adhesion due to particle 
shape or WSR (Figure 3.13).   
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Figure 3.12  Adhesion of spheres and rods with 1 µm ESD to activated ECs from 40% RBC in 
buffer at a fixed particle concentration of 5 x 105 #/mL.  Experiment was performed in a flow 
channel with a sudden expansion which causes recirculation flow to occur.  Data is plotted as a 
function of the distance downstream of the sudden expansion.  # = not significant (p > 0.01) 
compared to adhesion of spheres at the same WSR via one-way ANOVA, n ≥ 3. 
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Figure 3.13  Adhesion of spheres and rods with 500 nm ESD to activated ECs from 40% RBC in 
buffer at a fixed particle concentration of 5 x 105 #/mL.  Experiment was performed in a flow 
channel with a sudden expansion which causes recirculation flow to occur.  Data is plotted as a 
function of the distance downstream of the sudden expansion.  # = not significant (p > 0.01) 
compared to adhesion of spheres at the same WSR via one-way ANOVA, n ≥ 3. 
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3.3 Discussion 
 Many parameters must be considered when designing vascular-targeted drug delivery 
systems.  Previous works have investigated many different types of drug carriers, such as 
polymer matrices, liposomes, dendrimers, lipomers, microbubbles, etc.17–25  Other studies have 
investigated bond strength and specificity of candidate ligand-receptor pairs.26,27  Size has also 
been shown to have an effect on the margination of spheres to the CFL from blood flow.1–4  
Particle shape is a parameter that is similarly proposed to have an effect on the blood flow 
margination of drug carriers to the endothelium.  However, limited experimental evidence exists 
in the literature to this end.  In this study, we sought to examine the effect that particle shape 
parameters (volume, axis length, aspect ratio) have on the adhesion of vascular wall targeted rods 
and spheres from various physiological blood flow profiles via parallel plate flow chamber 
(PPFC) assays with an inflamed HUVEC monolayer lining the flow chamber wall.  Overall, our 
data shows that rod-shaped particles having volume equal to or greater than a 1 μm spherical 
volume (ESD ≥ 1 μm) and with AR ≥ 9 displayed enhanced adhesion compared to their spherical 
counterparts at high shear rates in laminar, pulsatile, and recirculation flow profiles.  At the 
largest particle volume explored (ESD = 2 μm), targeted rods with AR-9 showed over 2.2 fold 
more adhesion to the EC wall than equivalent spheres in laminar flow at a shear rate of 1000 s-1.  
We find similar results for 2 µm ESD disks, which display significantly greater adhesion at 1000 
s-1, but no difference at lower shear rates.  Spheres with 2 μm diameters, much like platelets, 
have been shown to be able to localize to the CFL efficiently in the presence of RBCs.  Thus, the 
increase in adhesion seen for rods and disks with 2 μm ESD can in part be attributed to better 
adhesive properties, such as a larger contact area with the vascular wall compared to the other 
particles and a streamlined shape.  This assertion is supported by the particle flux normalized 
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adhesion data (Figure 3.1B) – where the adhesion efficiency of 2 μm spheres in flow decreased 
as the WSR increased, while the adhesion efficiency of the AR-9 rods remained the same even at 
higher shear rates.  Particle elongation increases the particle surface area in contact with the 
endothelium and thereby presents a greater number of targeting ligand (in this case sLea 
molecules) to the endothelium when particles had a fixed ligand site density.  However, adhesion 
assays performed with a fixed total sLea number on 2 μm ESD particles indicate that the higher 
total number of sLea on rods is not the sole cause for the increased adhesion displayed by AR-9 
rods in the fixed ligand density assays.  Likely also important is the fact that the higher contact 
area with the endothelium exhibited by rods and disks distributes their adhesive force over a 
larger surface area, which would increase the shear force necessary to remove an adherent 
particle from the endothelium.  Furthermore, the streamlined shape of ellipsoids reduces the 
removal force due to blood flow felt by these particles at the endothelium compared to an 
equivalent sphere.  These combined effects have been predicted in silico13 and shown in buffer 
flow adhesion assays14,15 to improve particle adhesion dynamics.   
 Previous works have shown that spherical particles with diameters less than 2 μm do not 
effectively marginate to the vessel wall from bulk blood flow.1–4  Our laminar flow data agrees 
with this in that under the same blood flow conditions, particles of all shapes with ESD ≤ 1 μm 
displayed significantly lower localization to the CFL, as visualized via confocal microscopy.  
Further, 2 μm diameter spheres in the presence of RBCs produced a greater than 1 to 1 response 
in near-wall fluorescence following an increase in particle concentration, while 500 nm diameter 
spheres produced a less than 1 to 1 response (Figure 3.7), indicating the importance of particle 
size in determining localization to the CFL.  This translated to lower adhesion to the endothelium 
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than particles of the same shape with ESD of 2 μm for all WSR explored, despite being fed into 
the PPFC at the same concentration.   
 More importantly, most rods with ESD ≤ 1 μm evaluated in laminar RBC flow displayed 
the same or slightly worse adhesion density than equivalent spheres.  However, the highest 
aspect ratio rods having 1 μm ESD (AR-11) displayed significantly higher adhesion than 
equivalent spheres; in this case over the entire range of shear rates investigated at 30% Hct and 
over 3 times higher than spheres at 1000 s-1.  At 40% Hct, adhesion between AR-11 rods and 
equivalent spheres was not significantly different at 200 s-1 WSR because the decreased CFL size 
caused the spheres adhesion level to improve to that shown for AR-11 rods.  It seems likely that 
for 1 μm ESD particles, the rod shape – in addition to the favorable adhesion characteristics 
mentioned in the previous paragraph – improves particle transport to the vessel wall compared to 
spheres.  This assertion is supported by the 2 – 2.5 times higher adhesion for AR-11 rods at the 
lowest WSR explored with 30% Hct, a condition in which adhesion is not expected to be 
reaction-limited.1  In this case, the higher surface contact area exhibited by AR-11 rods and their 
streamlined shape that enhance reaction kinetics are expected to be inconsequential as was the 
case for 2 μm ESD particles at this condition (Figure 3.1, 200 s-1 WSR).  Two possibilities seem 
likely for this improved adhesion density for the AR-11 rods: (1) more of these rods may be 
excluded from the RBC core and into the CFL, i.e. they exhibit enhanced near-wall excess and/or 
(2) particles already within or near the CFL could better initiate contact with the vessel wall 
compared to particles with shorter axis lengths due to their major axis (~6 μm major axis for AR-
11, 1 μm ESD rods) being on the order of CFL size28, thus resulting in greater adhesion 
probability.  When localization was imaged using confocal microscopy, less AR-11 rods were 
seen in the CFL than equivalent spheres under the same conditions that enhanced adhesion of 
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AR-11 was observed – indicating that the second possibility is most likely the reason for the 
improved adhesion of AR-11 rods with 1 μm ESD compared to equivalent spheres at low shear 
rate.  The higher probability of contact for rods already within the CFL also agrees with the 
notion that rods in shear flow exhibit a lateral drift, which reduces margination time resulting in 
enhanced adhesion.11,12 
 Blood flow in areas of the vasculature where atherosclerotic plaques preferentially 
accumulate is often characterized by disturbed flow profiles including high pulsatility, low net 
shear due to reverse flow, and recirculation eddies near areas of bifurcations or high curvature.  
For this reason, adhesion experiments were performed in these relevant disturbed flow profiles.  
The disturbed flow assays revealed similar trends as was seen in laminar, steady flow.  
Compared to spheres with a 2 μm diameter, the AR-9 rods with 2 μm ESD exhibited the highest 
positive differential in adhesion from recirculating flow as well as in both pulsatile flow profiles 
(characterized by either alternating low/high shear forward flow or alternating forward/reverse 
high shear flow).  Similarly, only AR-11 rods with 1 μm ESD displayed a robust improvement in 
adhesion relative to spheres in recirculating and both pulsatile flow profiles evaluated.  Again, 
shape did not improve adhesion compared to spheres for particles with 500 nm ESD in disturbed 
flow patterns despite conditions which allow particles more residence time within the flow 
chamber (Figure 3.10B) and particle redistribution to the wall (recirculation flow).2   
 Overall, it is possible that a minimum major axis length for rods, rather than a minimum 
aspect ratio, is requisite for enhanced transportation to the wall, much like it has been shown that 
a minimum particle diameter is required for effective margination of spheres (~2 µm diameter).  
Of the 500 nm ESD particles used in this study, the highest aspect ratio rod evaluated (AR-10) 
had a major axis of 2.4 µm.  Even at this high aspect ratio, the adhesion was minimal as it was 
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for all 500 nm particles investigated.  Meanwhile, the major axis length for the 1 µm ESD rods 
(AR-11) that displayed enhanced adhesion compared to spheres was ~6 µm.  Also, 1 µm ESD 
rods with a major axis of 2.76 µm (AR-4) did not consistently show significant positive 
differential in binding relative to spheres under the flow conditions explored.  In line with our 
observations, Decuzzi et al presented a model which predicts that the lateral drift velocity of 
discoidal particles increases, i.e. faster collision with the wall, with increased particle 
elongation11; however, this work did not explicitly include high aspect ratio nanoparticles with a 
micrometer scale major axis dimension as was evaluated here.  Our current rod fabrication 
technique limits our capacity to fabricate rods of 500 nm ESD with major axis greater than 2.5 
µm and thus limits our capacity to test this hypothesis in this work.   
 Finally, it remains possible that particles of other non-spherical shapes having volume in 
the nanometer ESD range may exhibit enhanced margination in blood relative to equivalent 
spheres.  For instance, Decuzzi and co-workers recently showed that nanodisks in low shear 
buffer flow exhibit ~2 fold increased adhesion over rods of equal volume due to slightly higher 
hydrodynamic forces exerted on the rods compared to disks and the larger surface for adhesion 
exposed by disks relative to rods.15  However, our results show no indication that disks provide 
improvement over spheres or rods at the 500 nm or 1 µm ESD size when in the presence of 
RBCs.  Overall, the presented work shows that indeed particle shape can affect particle 
margination, thus should be considered in the design of VTCs. 
 
References 
1. Charoenphol, P., Huang, R. B. & Eniola-Adefeso, O. Potential role of size and 
hemodynamics in the efficacy of vascular-targeted spherical drug carriers. Biomaterials 
31, 1392–1402 (2010). 
60 
 
2. Charoenphol, P. et al. Targeting therapeutics to the vascular wall in atherosclerosis-
Carrier size matters. Atherosclerosis 217, 364–370 (2011). 
3. Tilles, A. W. & Eckstein, E. C. The near-wall excess of platelet-sized particles in blood 
flow: its dependence on hematocrit and wall shear rate. Microvasc. Res. 33, 211–223 
(1987). 
4. Eckstein, E. C., Tilles, A. W. & Millero  3rd, F. J. Conditions for the occurrence of large 
near-wall excesses of small particles during blood flow. Microvasc Res 36, 31–39 (1988). 
5. Namdee, K., Thompson, A. J., Charoenphol, P. & Eniola-Adefeso, O. Margination 
propensity of vascular-targeted spheres from blood flow in a microfluidic model of human 
microvessels. Langmuir 29, 2530–2535 (2013). 
6. Champion, J. A. & Mitragotri, S. Shape induced inhibition of phagocytosis of polymer 
particles. Pharm. Res. 26, 244–249 (2009). 
7. Champion, J. A. & Mitragotri, S. Role of target geometry in phagocytosis. Proc Natl Acad 
Sci U S A 103, 4930–4934 (2006). 
8. Decuzzi, P. et al. Size and shape effects in the biodistribution of intravascularly injected 
particles. J Control Release 141, 320–327 (2010). 
9. Geng, Y. et al. Shape effects of filaments versus spherical particles in flow and drug 
delivery. Nat Nanotechnol 2, 249–255 (2007). 
10. Muro, S. et al. Control of endothelial targeting and intracellular delivery of therapeutic 
enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 16, 
1450–1458 (2008). 
11. Lee, S. Y., Ferrari, M. & Decuzzi, P. Shaping nano-/micro-particles for enhanced vascular 
interaction in laminar flows. Nanotechnology 20, (2009). 
12. Gavze, E. & Shapiro, M. Motion of inertial spheroidal particles in a shear flow near a 
solid wall with special application to aerosol transport in microgravity. J. Fluid Mech. 
371, 59–79 (1998). 
13. Decuzzi, P. & Ferrari, M. The adhesive strength of non-spherical particles mediated by 
specific interactions. Biomaterials 27, 5307–5314 (2006). 
14. Doshi, N. et al. Flow and adhesion of drug carriers in blood vessels depend on their shape: 
A study using model synthetic microvascular networks. J. Control. Release 146, 196–200 
(2010). 
15. Adriani, G. et al. The preferential targeting of the diseased microvasculature by disk-like 
particles. Biomaterials 33, 5504–5513 (2012). 
61 
 
16. Charoenphol, P., Onyskiw, P. J., Carrasco-Teja, M. & Eniola-Adefeso, O. Particle-cell 
dynamics in human blood flow: implications for vascular-targeted drug delivery. J 
Biomech 45, 2822–2828 (2012). 
17. Backer, M. V et al. Vascular endothelial growth factor selectively targets boronated 
dendrimers to tumor vasculature. Mol. Cancer Ther. 4, 1423–1429 (2005). 
18. Unger, E., Porter, T., Lindner, J. & Grayburn, P. Cardiovascular drug delivery with 
ultrasound and microbubbles. Adv. Drug Deliv. Rev. 72, 110–126 (2014). 
19. Ting, C. Y. et al. Concurrent blood-brain barrier opening and local drug delivery using 
drug-carrying microbubbles and focused ultrasound for brain glioma treatment. 
Biomaterials 33, 704–712 (2012). 
20. Nance, E. et al. Brain-Penetrating Nanoparticles Improve Paclitaxel Efficacy in Malignant 
Glioma Following Local Administration. ACS Nano (2014). doi:10.1021/nn504210g 
21. Shuvaev, V. V. et al. Endothelial targeting of antibody-decorated polymeric filomicelles. 
ACS Nano 5, 6991–6999 (2011). 
22. Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O. C. 
Targeted polymeric therapeutic nanoparticles: design, development and clinical 
translation. Chem. Soc. Rev. 41, 2971 (2012). 
23. Muro, S. et al. Endothelial targeting of high-affinity multivalent polymer nanocarriers 
directed to intercellular adhesion molecule 1. J. Pharmacol. Exp. Ther. 317, 1161–1169 
(2006). 
24. Allen, T. M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. 
Trends Pharmacol. Sci. 15, 215–220 (1994). 
25. Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: From concept to clinical 
applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013). 
26. Byrne, J. D., Betancourt, T. & Brannon-Peppas, L. Active targeting schemes for 
nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60, 1615–1626 (2008). 
27. Eniola, A. O., Krasik, E. F., Smith, L. A., Song, G. & Hammer, D. A. I-domain of 
lymphocyte function-associated antigen-1 mediates rolling of polystyrene particles on 
ICAM-1 under flow. Biophys. J. 89, 3577–3588 (2005). 
28. Sharan, M. & Popel, A. S. A two-phase model for flow of blood in narrow tubes with 
increased effective viscosity near the wall. Biorheology 38, 415–428 (2001).  
 
62 
 
 
 
CHAPTER 4: SHAPE EFFECTS ON THE IN VIVO TARGETING AND 
BIODISTRIBUTION OF ELLIPSOIDAL PARTICLES IN 
ATHEROSCLEROTIC MICE 
 
This work is a collaboration with Katawut Namdee, and is published as K Namdee*, AJ 
Thompson*, A Golinski, S Mocherla, D Bouis, and O Eniola-Adefeso. In vivo evaluation of 
vascular-targeted spheroidal microparticles for imaging and drug delivery application in 
atherosclerosis. Atherosclerosis 237 (1), 279-286 (2014).1  *Authors had equal contribution to 
this work. 
 
ABSTRACT 
 Vascular-targeting is a promising strategy for improving the diagnosis and treatment of 
coronary artery disease (CAD) by providing localized delivery of imaging and therapeutic agents 
to sites of atherosclerosis.  Targeting particles to atherosclerosis is especially challenging in that 
particles must be able to marginate to the endothelium in relatively large vessels and in the 
presence of high shear rates due to blood flow.  In this work we evaluate how particle size and 
shape affects the capacity of a vascular-targeted carrier system to bind to inflamed endothelium 
over plaque using ApoE-/- mice with developed atherosclerosis.  Spherical and prolate 
ellipsoidal particles with either 500 nm or 2 µm equivalent spherical diameters (ESD) targeted to 
the inflammatory receptors E-selectin and VCAM-1 were injected via tail-vein and allowed to 
circulate for 30 min.  The entire aorta and major organs (lung, liver, spleen, and kidney) were 
excised and analyzed for particle targeting and accumulation.  We found that targeted ellipsoidal 
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microparticles adhered to mouse aortae at higher levels than microspheres of similar volume, 
particularly at segments that contained atherosclerotic plaques.  Moreover, both ellipsoidal and   
spherical nanoparticles displayed the same minimal adhesion levels compared to both types of 
microparticles evaluated, likely due to poor localization of nanoparticles to the vessel wall in 
blood flow.  We found that microparticles targeted to plaque-associated inflammation were 
retained at higher levels in the lungs than untargeted particles, largely due to molecular 
interaction with the pulmonary endothelium.  The level of mechanical entrapment of ellipsoidal 
microparticles in the lungs was also not significantly different from that of microspheres of the 
same volume despite a 3 fold higher major axis length for the ellipsoids.  This study confirms 
that particle shape and size should be considered in designing carrier systems to target 
atherosclerosis, as these parameters can be tuned to improve carrier performance. 
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4.1 Introduction 
Vascular-targeted carriers is a promising potential strategy for improving treatment of 
atherosclerosis because specific vascular wall endothelial cell receptors associated with acute 
and chronic inflammation (selectins, ICAM-1, VCAM-1) play a major role in the pathology of 
this disease.  Naturally, these receptors then also provide a convenient and accessible platform 
for vascular targeting.  Current vascular-targeting strategies in coronary artery disease (CAD) 
typically involve coating injectable carriers with targeting moieties for specific interaction with 
the relevant endothelial expressed receptors, providing these carriers the ability to navigate the 
vasculature, adhere, and persist locally in the diseased tissue.  Overall, the ability to provide 
highly localized delivery to atherosclerotic pre-lesions or fully formed plaques in CAD can offer 
new therapeutic avenues for early diagnosis and treatment of this disease.2 
Many variants of VTCs have been investigated for use as a diagnostic or therapeutic, such 
as polymer particles, liposomes, dendrimers, and polymersomes; which are typically spherical 
with nanoscale diameters.3  However, particle shape and size have recently been presented as 
tunable parameters for enhancing the vascular wall interaction of VTCs at a targeted site in the 
presence of blood flow.4–6 Numerous mathematical and some simple flow experimental models 
show that ellipsoidal particles can display greater deposition/adhesion compared to spherical 
particles of the same volume.7–10  Our recent in vitro study (Chapter 3) also shows that under 
physiological levels of shear, prolate ellipsoidal (rod-like) particles targeted to inflammation 
display higher levels of adhesion compared to spheres in the presence of human RBCs in parallel 
plate flow chamber assays, provided that the equivalent spherical diameter (ESD) of the rods is ≥ 
1 μm.11  To our knowledge, the in vivo study presented here is the first to compare adhesion of 
spherical and ellipsoidal polymer VTCs within the context of targeting atherosclerotic plaques in 
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CAD.  The areas of the vasculature vulnerable to atherosclerosis tend to be large vessels (on the 
order of centimeters in diameter in humans), which make the successful localization of VTCs to 
the vascular wall increasingly important in determining their overall performance.  Further, these 
atheroprone areas tend to exhibit pulsatile and disturbed blood flow profiles which are very 
different in terms of hemodynamics compared to the microvasculature, where much of the 
previous vascular targeting research has been focused.12  Here, we evaluate the role that the size 
and shape of particles has on their capacity to effectively reach and bind to inflamed aorta using 
a mouse model of atherosclerosis.  Specifically, we investigated the adhesion levels of prolate 
ellipsoidal and spherical particles along sections of the aorta from the aortic root to the iliac 
branches, and the effect of the targeting ligands on the biodistribution of spherical and ellipsoidal 
particles in major organs.  Particles were dual-targeted to the inflammatory receptors E-selectin 
and VCAM-1, which are proteins known to be overexpressed by the endothelium in 
atherosclerosis.13–15  A dual-targeting approach is employed based on previous publications that 
suggest in vivo selectivity to ECs over plaque in ApoE -/- mice is greatest when both VCAM-1 
and selectin were targeted.16,17  We found that targeted rod-shaped microparticles adhered to 
mouse aortae at overall higher levels than spherical microparticles, particularly at segments of 
the aorta that contained developed or developing plaques.  There was no difference in the 
adhesion of rod-shaped and spherical nanoparticles, which was minimal to the adhesion of 
microparticles.   
4.2 Results 
Prolate ellipsoidal particles were fabricated using a previously described11,18,19 polymer 
film stretching method before coating the surface with sLea and aVCAM-1 to target E-selectin 
and VCAM-1, respectively (see Chapter 2).  Particles were administered to 20 week old mice at 
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a dosage of 20 x 106 particles per mouse via the tail-vein and allowed to circulate for 30 min 
before analyzing particles adherent to the aorta and particle biodistribution.   
4.2.1 Particle adhesion to aorta 
As in Chapter 3, we are interested in exploring which aspect ratio (AR) results in the best 
targeting, in this case to inflamed aorta.  In order to determine the effect that AR has on targeting 
ability, targeted rods of three different ARs (2, 4, 9) with 2 μm ESD as well as 500 nm and 2 μm 
spheres were prepared.  Figure 4.1 shows the SEM images and Table 4.1 gives the dimensions of 
the 2 μm rods and equivalent spheres used to test the effect of AR on targeting in mice. 
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Figure 4.1  SEM Images of 2 µm ESD polystyrene (A) spheres, (B) AR-2 rods, (C) AR-4 rods, 
and (D) AR-9 rods used to test the effect of aspect ratio on particle adhesion to the aorta in 
ApoE-/- mice.  Scale bar = 5 µm. 
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Table 4.1  Dimensions of particles used to test the effect of AR on particle adhesion. 
 
Following tail-vein injection into ApoE-/- mice, adhesion of each particle type to the 
aorta was quantified and normalized to the average amount of adherent 500 nm diameter spheres 
(Figure 4.2).  The adhesion of the AR4 rods was the highest (~3 times higher) relative to their 
equivalent microspheres.  Adhesion of AR2 rods was roughly the same as 2 μm spheres, likely 
because of the relatively small difference in shape and surface area between these two shapes.  
Adhesion of AR9 rods was statistically the same as the 2 μm spheres and lower than that of AR4 
rods, despite displaying the highest adhesion in the in vitro human blood assays (Chapter 3). This 
change in optimum AR is potentially due to increased entrapment of AR9 rods in the capillaries 
as they have a major axis length of roughly 9 μm.  Also, mouse RBCs have different 
characteristics compared to human RBCs such as diameter, volume, and tendency to form RBC 
aggregates; which could affect which particle AR is ideal for margination and adhesion. 
  
Particle Shape ESD (μm) Aspect Ratio Major Axis (μm) Minor Axis (μm)
Sphere 1.00 2.07 2.07
AR-2 2.25 3.55 1.58
AR-4 4.46 5.61 1.26
AR-9 9.45 9.25 0.98
2.07
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Figure 4.2  Ratio of the binding (normalized to 500 nm diameter sphere) of sLea and anti-VCAM 
coated particles of various AR on ApoE-/- mouse aortae after 30 min circulation via tail-vein 
injection.  (* = p < 0.05 and n.s. = not significant via one-way ANOVA, n ≥ 3). 
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Given the results in Figure 4.2, the following adhesion experiments were performed with 
the highest binding 2 μm rods (AR4), as well as 2 μm spheres, 500 nm spheres, and 500 nm rods 
with AR6.  Figure 4.3 shows the average cumulative particle adhesion along the entire length of 
the aortic tree normalized to the adhesion of 500 nm spheres, from the ascending aorta to the 
iliac branching points.  Particles with 2 μm ESD displayed significantly higher adhesion 
densities, at least 4 fold, compared to particles with 500 nm ESD.  When adhesion data is 
normalized for particle volume (relevant for drug loading), the cumulative volume delivered by 
adherent microparticles is ~500-1500 fold higher than the volume of adherent nanoparticles 
depending on particle shape (Figure 4.4).  Nanorods displayed no increased adhesion compared 
to their equivalent 500 nm diameter spheres.  Control experiments with targeted 2 μm spheres 
injected into wild type mice or 2 μm IgG-coated particles (spheres and AR4 rods) injected into 
ApoE-/- mice show minimal accumulation in the aorta, suggesting that the high adhesion of 
targeted microparticles observed in the aorta of ApoE-/- mice are due to the expression of the 
targeted inflammatory molecules on the endothelium. 
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Figure 4.3  (A) Ratio of the adhesion of sLea and anti-VCAM targeted particles on ApoE-/- 
mouse aortae following 30 min circulation via tail-vein injection.  AR = 6 and 4 for rods with 
ESD of 500 nm and 2 µm, respectively (* = p <0.05 with respect to 2 µm microspheres and n.s. 
= not significant via one-way ANOVA, n ≥ 5).  (B) Ratio of the adhesion of sLea and anti-
VCAM targeted 2 µm spheres to wild-type mouse aortae or of IgG-coated 2 µm spheres and rods 
(AR4) to ApoE-/- mouse aortae following 30 min circulation via tail-vein injection. 
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Figure 4.4  Ratio of volume binding (normalized to 500 nm ESD rod) of sLea and anti-VCAM 
coated particle binding on ApoE-/- mouse aorta after 30 min circulation via tail-vein injection, n 
≥ 5. 
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It is established that atheroprone areas of the aorta are typically near vessel bifurcations 
or curvature, whereas the blood flow profiles along straight sections of the aorta tend to be 
atheroprotective.20–22  Therefore, we also quantified the adhesion density of targeted particles 
along different sections of the aorta from the ascending aorta to the iliac branches.  At each 
section investigated, the adhesion density of 2 μm rods was greater than or equal to the adhesion 
of equivalent spheres (Figure 4.5).  Interestingly, the adhesion density of targeted microrods 
relative to microspheres and nanoparticles was greatest around the combined area of the 
brachiocephalic, right common carotid, and right subclavian branching points near the aortic 
arch, followed by the thoracic aorta and to a lesser extent the descending aorta.  Visual 
inspection revealed developed/developing plaques near many of the branched and curved regions 
of the vasculature.  Qualitatively, adhesion of targeted particles was higher on or near these 
regions of plaque formation.  As shown in Figure 4.6, a representative Hoecsht (nucleus) and 
wheat germ agglutinin (plasma membrane) staining of a segment of the aorta with visible plaque, 
more microparticles were bound around the periphery of the developing plaque than on the top.  
Overall, adhesion was minimal for nanoparticles throughout the aorta compared to 
microparticles, even in areas where very high levels of inflammation are expected 
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Figure 4.5  Ratio of particle binding of sLea and anti-VCAM coated particles to the endothelium 
in 12 segments along mouse aorta.  (* = p < 0.05 with respect to 2 µm microspheres, n ≥ 4).  
Adhesion data shown is normalized to the averaged to the number of 500 nm diameter spheres 
bound per segment. 
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Figure 4.6  Representative images of aortic arch segments (with atherosclerotic plaque present) 
with adhesion of 2 µm ESD spheres (A and B) and 2 µm ESD rods (C and D) at 20x and 60x 
magnification, respectively, qualitatively showing the increased adhesion of rods particularly 
near the periphery of plaques.  Blue – nucleus stained by Hoechst, Red – plasma membrane 
stained by Alexa Fluor conjugate of wheat germ agglutinin and Green – fluorescent particle. 
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4.2.2 Particle biodistribution to major organs 
Major organs were harvested from animals injected with targeted particles to quantify the 
biodistribution of microrods relative to its equivalent sphere and nanospheres.  Figure 4.7 shows 
the accumulation of targeted particles in the lung, liver, spleen, and kidney.  Blood collected 
following a 30 min circulation time contained negligible amounts of particles.  Targeted AR4 
microrods were retained at a higher level in the lungs than 2 μm or 500 nm diameter spheres.  
These same rods were retained at either equal or significantly lower levels than 
micro/nanospheres in the other organs, potentially because the higher level of first-pass lung 
accumulation and adhesion to the aorta reduces the amount available to accumulate elsewhere.  
The 500 nm spheres accumulated at higher levels in the liver than the larger microparticles, and 
there was no appreciable difference in the splenic accumulation of micro and nanoparticles.  
Retention of particles in the kidneys was low, as particles larger than about 50-100 nm are not 
expected to be removed from blood via glomerular filtration.   
The higher accumulation of targeted rods in the lungs may be due to physical entrapment 
of rods (major axis = 5.6 μm) in the small capillaries of the lungs or due to the surface targeting 
ligands allowing molecular interaction to increase adhesion of particles to the lung endothelium.  
To investigate this further, uncoated rods and spheres were injected into wild-type mice in the 
same manner that targeted particles were injected into ApoE-/- mice.  As shown in Figure 4.7B, 
retention of untargeted microspheres and the AR4 microrods in the lungs was about 87% and 
93% lower, respectively, than targeted particles of the same size and shape.  Retention of 
untargeted microspheres and microrods was about 605 and 280% higher in the liver and about 
81% and 140% higher in the spleen, respectively, than the equivalent targeted particle.  When 
each dataset presented in Figure 4.7 is normalized to the density of each particle type 
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accumulating in the lungs, the targeted microspheres were found to accumulate in similar 
amounts in the lung, liver, and spleen while targeted microrods accumulated primarily in the 
lungs (Figure 4.8).  However, untargeted microspheres and microrods both displayed the 
majority of accumulation in the liver and spleen. 
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Figure 4.7  (A) Biodistribution of sLea and anti-VCAM coated spheres (500 nm or 2 µm 
diameters) and rods (2 µm ESD, AR4) in ApoE-/- mice following 30 min circulation via tail-vein 
injection, n ≥ 5.  (B) Biodistribution of untargeted spheres (2 µm diameter) and (2 µm ESD, 
AR4) in wild type mice following 30 min circulation via tail-vein injection. (* = p < 0.05 relative 
to 2 µm spheres and # = p < 0.05 relative to the 500 nm spheres via one-way ANOVA, n ≥ 4). 
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Figure 4.8  Ratio of the accumulation density in major organs (%ID/g organ) to the accumulation 
density in the lungs (%ID/g lungs) for (A) targeted and (B) untargeted 2 µm spheres and rods (2 
µm ESD, AR4) in mice following 30 min circulation via tail-vein injection, n ≥ 4. 
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4.3 Discussion 
 Particle shape is now known to be a parameter that can be tuned to affect the circulation 
time, biodistribution, adhesion, internalization, and intracellular trafficking of vascular-targeted 
carrier systems.23–33  This work demonstrates that the size and shape of vascular-targeted 
particles plays a role in prescribing their adhesion to sites of atherosclerosis and accumulation in 
major organs in mice.  In order for particles to adhere to inflamed endothelium, they must be 
able to effectively marginate to the vessel wall – analogous to how circulating immune cells and 
platelets are able to localize to inflamed/damaged endothelium even in large diameter vessels.  
Previous works have demonstrated that particle size (spherical diameter) plays a crucial role in 
the ability or inability of a particle to preferentially marginate in the presence of human blood 
components (RBC, plasma) using in vitro models of flow in blood vessels.5,6,11,34–36  In general, 
particles that have diameters (or equivalent spherical diameter) less than about 2 μm do not 
segregate to the cell-free layer, and hence minimally adhere to inflamed ECs at the wall, in blood 
flow as efficiently as particles with diameters  ≥  2 μm.6,11,34–36  Instead, evidence suggests these 
sub-micron to nanoscale particles preferentially remain in the core of flow, encased by RBCs.6  
Concordantly, in this study we find significantly lower adhesion of targeted nanospheres and 
nanorods of 500 nm ESD along the inflamed mouse aorta compared to microparticles.  Also, the 
enhanced adhesion of microrods to the aorta (roughly 4 fold) compared to equivalent 
microspheres is in line with our previous observation of particle localization in human blood in 
vitro where microrods (≥ 1 μm ESD) were found to adhere at higher levels than equivalent 
spheres.11  This increased adhesion for microrods in vivo over their equivalent spheres is likely 
due to more favorable adhesive characteristics rather than improved localization to the wall, 
including a higher contact surface area and a streamlined shape to reduce drag in the presence of 
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blood flow induced shear, since no improvement was found in the localization of rod-shaped 
particles to the CFL in human blood flow in PPFC assays compared to equivalent spheres.11  The 
lack of improved adhesion of nanorods compared to nanospheres is likely due to the inability of 
nanoparticles to preferentially segregate to the CFL regardless of shape and the diminished 
impact of higher contact surface area and reduced drag on adhesion for these particles.  While 
particles on the nanometer scale may have benefits in terms of circulation time and ability to 
transmigrate across the endothelium, this inability of nanoparticles to adhere to the endothelium 
in the aorta could potentially limit their efficacy as a vascular-targeted carrier system for diseases 
affecting medium/large blood vessels. 
It has been shown that specific areas of the arterial tree are predisposed to atherosclerotic 
lesion formation, referred to as “atheroprone”.  These atheroprone areas include the aortic root, 
the curvature along the aortic arch, and major branching points along the arterial tree; and 
typically are exposed to disturbed blood flow, characterized by high pulsatility but low net 
shear.12,37  We see significantly increased adhesion of microrods compared to spheres in many 
atheroprone areas, particularly near major branching points in the aorta.  Particle adhesion 
associated with plaques was found preferentially around the periphery of the plaque, which 
agrees with previously reported findings for the adhesion of VCAM-1 targeted polymeric 
particles.38  This patterning is very likely related to the expression patterns of the target 
molecules,, particularly VCAM-1, which have been shown to persist on ECs adjacent to plaques 
more so than directly on top of plaques within ApoE-/- mice.13 
Previous research has also demonstrated that particle shape, size, and the presence of 
targeting ligands can affect biodistribution in mice.23,30,33,38,39, and in this study we indeed see the 
biodistribution profile altered based on these parameters.  As expected, we see accumulation of 
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particles in the lung and liver, with accumulation to a lesser extent in the spleen and kidneys.  
We find significantly more targeted 2 μm ESD rods in the lungs compared to equivalent spheres, 
which could be a function of either (1) mechanical entrapment due to the longer axis length of 
the rod or (2) enhanced molecular interactions of the targeting ligands on rods with pulmonary 
endothelium.  Research has correlated accelerated pulmonary endothelial inflammation with the 
presence of systemic atherosclerosis,40 so some level of accumulation based on molecular 
interaction with targeting ligands could be occurring.  Indeed, the significantly lower 
accumulation of uncoated microparticles in the lung suggests that a significant portion of the 
lung accumulation is due to molecular interaction of the targeting molecules with the pulmonary 
endothelium and would be exaggerated for the microrods versus spheres due to the former 
having a larger surface area for contact (i.e. more favorable adhesion kinetics) and streamlined 
shape (reduced removal force).  Interestingly, the mechanical entrapment of the AR4 microrods 
(i.e., non-targeted particles) in our study is not significantly different from that of equivalent 
spheres despite having quite different major axis lengths which would suggest that the rods 
preferentially enter the capillaries in an orientation that align their major axis in the direction of 
flow.  Overall, our results suggest that the future use of prolate ellipsoids, or other spheroidal-
shaped particles, for imaging and drug delivery in atherosclerosis may require the targeting of 
non-inflammatory molecules specifically overexpressed by the endothelium over plaque but not 
in the lungs to minimize excessive carrier accumulation and hence prevent signal interference 
from the lungs in the case of imaging application or unwanted release of cytotoxic/potent agents 
in the lungs in the case of therapeutic application.  Alternatively, rod-shaped microcarriers can be 
used as a combination therapy where patients are given anti-inflammatory drugs to reduce 
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inflammation in the lungs prior to injection of rod microcarriers for vascular-targeting in the 
aorta. 
 Finally, the overall biodistribution profile of microparticles being shifted towards more 
accumulation n the liver and spleen when targeting ligands are removed from particle surfaces is 
likely due to the lower first-pass retention of untargeted particles in the lung (immediately 
following tail-vein injection) and no retention in the aorta, i.e., more untargeted particles 
available in circulation for hepatic/splenic clearance compared to targeted particles.  The overall 
observation of particle distribution in this work is in agreement with a previous study by Muro et 
al., which reported the accumulation of anti-ICAM targeted polystyrene disks in the lungs and 
liver of C57Bl/6 mice.23  This study found that targeted disks (0.1 x 1 x 3 μm dimensions) 
accumulated at high levels in the lungs and relatively low levels in the liver, and that retention of 
non-targeted (IgG coated) particles was diminished in the lungs, with a corresponding increase in 
liver accumulation.23  The liver accumulation of microparticles in our study (%ID/g) is 
somewhat higher than in other published reports, which may be due to differences in 
quantification techniques and also heterogeneity in the liver.  In this study, the left lobe of the 
liver from each animal was harvested after the animal is sacrificed and the circulatory system 
perfused with buffer and fixing agent.  It is possible that particles were disproportionately 
deposited in the left lobe than in the rest of the liver.  Indeed, it has been shown that “portal 
streamlining” can result in incomplete blood mixing causing variation in blood delivered to liver 
lobes and hence disproportionate deposition of particles between the two lobes.41  Also, blood 
from the spleen or stomach tends toward the left side of the liver.41  Furthermore, others have 
published in vivo studies with fluorescent images that seem to suggest heterogeneous particle 
deposition in the liver.42,43 
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 In conclusion, we confirmed that prolate ellipsoidal microparticles of an intermediate 
aspect ratio (AR4) with volume equivalent to 2 μm diameter sphere are more efficient than 
microspheres of equal volume and nanoparticles at targeting inflamed endothelium in the aortae 
of atherosclerotic mice, particularly in atheroprone areas.  Further, these microrods when 
untargeted displayed a similar level of minimal mechanical entrapment in the lung capillaries 
compared to their spherical counterparts.  Thus, the ellipsoidal geometry at the appropriate 
magnitude of elongation/aspect ratio may be an advantageous shape to design carriers for 
targeting the aorta, in order to deliver the highest possible payload of therapeutics or diagnostics 
intravenously in atherosclerosis.  However, targeted microrods, more so than microspheres and 
nanoparticles, are retained in the lungs at higher levels compared to their untargeted 
counterparts, likely due to molecular interaction with inflammatory molecules also expressed in 
the pulmonary vasculature of ApoE-/- mice.  Overall in this work we see that particle shape, 
particle size, and targeting moiety all indeed play a role in prescribing the adhesion and 
biodistribution profile in a mouse model of atherosclerosis – thus all of these parameters should 
be considered when designing carrier systems to target this disease. 
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CHAPTER 5: EFFECT OF PARTICLE DENSITY ON ADHESION OF 
VASCULAR-TARGETED CARRIERS IN VITRO 
 
 
ABSTRACT 
 For vascular-targeted carrier (VTC) systems to be effective, carriers must be able to 
localize and adhere to the target site from blood flow.  It has been shown that neutrally-buoyant 
nanoparticles are limited by their ability to localize to the endothelium, making them sub-optimal 
as carriers despite their many benefits including better evasion of the immune system and ease in 
navigating capillary beds.  Here we show that particle density is a parameter which can be 
exploited to improve the localization and adhesion of nanospheres, potentially making them 
more effective at accessing diseased tissues locally and specifically via the vasculature.  Using a 
parallel plate flow chamber assay method we see that silica (Si) spheres, which have a density 
roughly twice that of blood, consistently exhibits improved adhesion to inflamed endothelium 
compared to neutrally-buoyant polystyrene (PS) spheres with 500 nm diameters.  We see directly 
that Si spheres display improved near-wall localization when in the presence of RBCs compared 
to in pure buffer, likely resulting in the observed improvement in adhesion.  We find titania (Ti) 
spheres (4 times more dense than blood) adhere at levels higher than PS, but only in conditions 
where gravity or centrifugal force acts in the direction of adhesion; displaying the importance of 
other hemodynamic conditions such as channel orientation and shear rate in determining carrier 
targeting effectiveness.  Overall, we find that in the light of the wide array of materials proposed 
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for use as carrier systems for drug delivery and diagnostics, particle density may be a useful tool 
for improving the targeting of diseased tissues. 
91 
 
5.1 Introduction 
 The ability of vascular-targeted carriers to marginate, or localize and adhere to the 
periphery of the blood vessel, is an important requisite for successful targeting (i.e., binding) to 
the endothelium.  It has been established that particle size and geometry prescribes the ability of 
a particle to marginate in human blood flow.1–9   However, it is quite possible that other particle 
characteristics, in addition to size, may affect the margination propensity of a carrier system.  
One such parameter is particle density, which can be altered depending on the material makeup 
of the carrier system being employed.  To date, materials with a range of densities have been 
proposed for use in vascular-targeted drug delivery or diagnostics, including microbubbles10–12, 
polymers13–16, liposomes17,18, inorganic particles (titania, gold, iron oxide)19–21, blood cells22,23, or 
combinations of multiple material types24–26. Yet, there is limited understanding of the role that 
density plays in prescribing carrier performance relating to their margination and vascular wall 
adhesion.   
 Particle density forces seemingly could be regarded as negligible in describing particle 
motion relevant to physiological blood flow, since the hydrodynamic forces due to flow (for 
microparticles) and Brownian forces (for nanoparticles) are often orders of magnitude higher 
than density-dependent forces such as gravitational and centrifugal forces.27,28  However, the 
distance that a particle must travel in the normal direction to the endothelium to initiate contact 
may also be orders of magnitude shorter than the distance the particle travels in the transverse 
direction.  This is particularly true for particles already localized to the cell-free layer (CFL) 
which forms adjacent to the endothelium and has a height of only a few microns.29  
 It is widely known that red blood cells (RBC) play a crucial role in the margination of 
leukocytes and platelets.29,30  By congregating in the center of flow, RBCs force white cells and 
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platelets to concentrate in the CFL, aiding in their margination and interaction with the vascular 
wall.  This effect is in part due to the size of platelets (2-3 μm diameter) and white cells (8-12 μm 
diameter).31  It has been shown via in vitro models of human vasculature that neutrally-buoyant 
microspheres of sufficient size (≥2  μm diameter) can also take advantage of this phenomenon.1–7  
However, it has been shown experimentally and confirmed computationally that neutrally-
buoyant particles with diameters in the 100-500 nm size range are not preferentially distributed 
via this RBC effect, resulting in inefficient margination and sub-optimal targeting to endothelium 
in microchannels in the presence of physiological levels of RBCs.3,5,7,8  Still, particles in this size 
range are attractive and are typically proposed for vascular-targeted drug delivery in that they are 
able to carry a larger payload than ultra-small nanoparticles while still being able to safely 
navigate microvasculature.32–39 To date, it is unclear whether particle density affects the 
margination of larger nanoparticles or sub-micron sized particles to the CFL via interactions with 
RBCs in blood flow.  While a recent study shows that increasing particle density negatively 
affects nanoparticle margination in a microchannel40, this was done in the absence of blood 
components and with nanoparticles having 60-65 nm diameters whose density effects are much 
smaller compared to sub-micron sized particles.   
 Evidence exists in the literature that density may have a role on how efficiently platelets 
interact with the endothelium in blood flow.  Even in the small density range reported for sub-
populations of platelets (1.040-1.080 g/mL), it was found that the most dense platelets exhibited 
roughly 4 times higher initial adhesion than the least dense platelets.41  Materials proposed for 
vascular-targeting have a much wider range of particle densities, including bubbles (less dense 
than blood), neutrally-buoyant and non-neutrally buoyant polymers or lipid based particles, or 
more dense metal-based particles.42  Therefore, it is of interest to investigate how the interaction 
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between nanoparticles with red blood cells (RBC) affects margination when particle density is 
considered. 
 In this study, we investigate how the density-dependent forces (gravity, centrifugal), 
density-independent forces (hydrodynamic, Brownian), momentum, and adhesion dynamics 
combined with the presence of blood components prescribes the targeting of 500 nm diameter 
nanospheres to inflamed endothelium from human blood flow.  Further, we investigate how the 
gravity effects change the adhesion profile of targeted spheres when the chamber is oriented such 
that the direction of margination is either toward or away from gravity.  Using a recirculation 
flow setup we determine whether centrifugal force due to an induced recirculation eddy in the 
flow allows particles with higher densities to better target the endothelium compared to 
neutrally-buoyant particles.  Finally, we investigate how these in vitro results translate to the 
more complex in vivo environment using an inflamed mouse model.   
5.2 Results 
In this work, we employ an in vitro human blood flow assay to study the targeting ability 
of polystyrene (PS), silica (Si), and titania (Ti) spheres which have 500 nm diameter and 
densities of 1.05, 2.0, and 3.9 g/cm3, respectively, to the vascular wall in various blood flow 
conditions.  Briefly, particles are surface-coated with targeting ligands, mixed with buffer or a 
RBC-in-buffer mixture, and flowed through a parallel plate flow chamber (PPFC), which is lined 
with an inflamed monolayer of human umbilical vein endothelial cells (HUVEC).  Parameters 
such as shear rate, blood flow profile, chamber orientation and microchannel height are altered to 
determine how particle density causes differences in targeting affinity.    This in vitro model of 
blood flow in a vessel is a useful tool to predict the in vivo targeting ability of a carrier system to 
a multitude of diseased states, depending on the ligand-receptor system employed.  In this work, 
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we target acute inflammation that is relevant to many inflammatory diseases, including 
atherosclerosis and arthritis. 
5.2.1 Effect of RBCs on Particle Adhesion in Laminar Flow 
 Figure 5.1 compares the adhesion density of 500 nm diameter, vascular-targeted 
polystyrene (PS), silica (Si), and titania (Ti) spheres  following 5 min of either buffer flow or 
RBC-in-buffer flow over an inflamed HUVEC monolayer at a physiological shear rate of 500 s-1.  
Representative images of particles bound on HUVEC are shown in Figure 5.2.  In buffer flow 
(Figure 5.1A), particle adhesion to HUVEC at the bottom of the chamber increases with particle 
density, as Si and Ti spheres adhered 360% and 640% higher, respectively, than PS spheres 
(though the difference for Si and PS was not statistically significant).  
 Multiple interesting observations can be made when a physiologically relevant number of 
RBCs are added to the experimental setup (Figure 5.1B).  When the HUVEC monolayer is at the 
bottom of the chamber, the adhesion of Si and Ti spheres is 257% and 91% higher, respectively, 
than that of PS spheres.  When the chamber is inverted and binding is occurring against the 
direction of gravity, the adhesion of Si spheres is still 236% higher than that of PS spheres, while 
the adhesion of PS and Ti spheres was not significantly different.  Even with gravity force acting 
opposite the adhesive surface, Si particles still bind more than neutrally-buoyant PS. This 
suggests that Si spheres are potentially localizing to the wall, i.e. CFL, better than PS or Ti in the 
presence of RBC, particularly given that the average adhesion in upright buffer flow assays 
(Figure 5.1A) increased with increasing particle density. 
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Figure 5.1  Adhesion of sLea-coated PS, Si, and Ti spheres (500 nm diameter) to inflamed 
endothelium after 5 mins of particle-loaded (5x105 particles/mL total volume) buffer flow (A) or 
RBC-in-buffer flow (B) at a shear rate of 500 s-1.  Experiments were done with the endothelial 
layer at the bottom (upright) of the chamber in the buffer flow experiments, and chamber 
orientation was varied in the RBC-in-buffer flow experiments.  Student t-test were performed 
comparing particle adhesion to adhesion of *PS or #Si at the same chamber orientation.  A p 
value < 0.05 was considered statistically significant. 
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Figure 5.2  Sample images of sLea-coated (A) PS, (B) Si, and (C) Ti spheres (500 nm diameter) 
adhering to inflamed endothelium after 5 minutes of steady laminar particle-loaded (5x105 
particles/mL total volume) RBC-in-buffer flow at a shear rate of 500 s-1.  The chamber had a 
height of 254 µm and the orientation was upright. Scale bar = 100 µm. 
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5.2.2 Localization of Particles to the Red Blood Cell-Free Layer 
 In light of the observations seen in Figure 5.1, it is important to consider what 
mechanisms may cause the density-dependent differences in adhesion in the presence of RBCs.  
One possible behavior which could result in improved adhesion to the endothelium would be the 
improved localization of particles to the CFL, resulting in a higher number of particles with an 
opportunity to bind.  In order to investigate this, we utilize a previously described microchannel 
setup in which fluorescent particles localized to a near-wall focal plane are imaged using a 
confocal microscope.5,7 This setup decouples particle localization from the ligand/receptor 
adhesion to determine how the presence of RBCs affects only localization to the near-wall 
region.  As an upright confocal microscope was used, particles localized near the upper wall of 
the flow chamber are imaged. 
 Figure 5.3A shows the near-wall (within 2 μm distance from top wall) localization of PS, 
Si, and Ti particles from RBC-in-buffer flow in a microchannel under the same conditions as the 
adhesion experiment represented by Figure 5.1B (inverted).  On average, the Si particles 
localized the highest, followed by PS and then Ti particles (differences were not significant). 
Then, it is of interest to compare the particle localization in RBCs-in buffer flow to the near-wall 
localization in the absence of RBCs (Figure 5.3B).  Interestingly, the addition of RBCs results in 
a 13% increase in the amount of Si spheres localized to the near-wall region compared to 
particles in buffer flow, while adding RBCs results in a 12% and 4% decrease in the amount of 
near-wall localized PS and Ti spheres relative to buffer flow. 
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Figure 5.3  (A) Localization of PS, Si, and Ti spheres (500 nm diameter) to within 2 µm of the 
upper wall of a microchannel from particle-loaded RBC-in-buffer flow (5x105 particles/mL total 
volume) at 500 s-1, and (B) percent change in the particle localization between particle-loaded 
buffer flow and particle-loaded RBC-in-buffer flow under the same conditions.  Student t-test 
was performed comparing *particle localization and localization % change to that of PS.  A p-
value < 0.05 was considered statistically significant. 
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5.2.3 Effect of Shear Rate on Adhesion of Dense Particles 
 Based on the results shown in Figure 5.1 and Figure 5.3, we see evidence that Si spheres 
have higher adhesion from RBC-in-buffer flow than Ti spheres because Si are more effective at 
localizing to the CFL in the presence of RBCs.  Another factor which must be considered in the 
adhesion experiment once particles are in the CFL is the binding kinetics between the targeting 
ligands on the particle and the targeted receptors, countered by the fact that these particles carry 
translational momentum that the ligand/receptor interaction must overcome to result in firm 
adhesion.  At a given shear rate and ligand surface coverage, a Ti particle would need to 
overcome a higher force than a Si particle to firmly adhere.  Figure 5.4A shows the adhesion 
level of Si and Ti spheres to inflamed endothelium at a range of laminar shear rates (from 50-
1000 s-1) for a fixed experiment time of 5 min.  Also, data is normalized to the number of 
particles used per experiment (Figure 5.4B), so that the “adhesion efficiency” of particles at 
different shear rates can be properly compared.  At the lowest shear rates investigated (50, 100 s-
1), Si and Ti display the same adhesion and thus, adhesion efficiency.  At increasing shear rates 
of 200 and 500 s-1, the adhesion of Si spheres increases to a maximum at 500 s-1; followed by a 
significant decrease in adhesion at 1000 s-1.  At shear rates above 100 s-1, the Ti particles do not 
show a similar increase in adhesion as was seen for Si particles; and likewise, the adhesion 
efficiency decreases more than Si particles especially at 200 and 500 s-1.  At 1000 s-1, the 
adhesion efficiency of Si spheres decreases to a level not significantly different from that of Ti 
spheres.  Also, we can compare adhesion efficiency between particles at conditions when the 
momentum should be the approximately equal between Si and Ti spheres (Si at 100 s-1 versus Ti 
at 50 s-1, for instance).  At low shear, we do see that the heavier Ti spheres have better adhesion 
efficiency to the bottom of the chamber than Si spheres when the momentum is fixed. 
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Figure 5.4  Adhesion of sLea-coated Si and Ti spheres (500 nm ESD) to inflamed endothelium 
after 5 minutes of particle-loaded RBC flow (5x105 particles/mL blood) at various shear rates.  
Experiments were done with the endothelial monolayer at the bottom of the chamber.  Student t-
tests were performed comparing *Si and Ti adhesion at a given shear rate.  A p-value < 0.05 was 
considered statistically significant. 
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5.2.4 Recirculation Flow: Effect of Induced Eddy on Adhesion 
 Some chronic inflammatory diseases including atherosclerosis are known to form in areas 
of the vasculature characterized by disturbed flow profiles (recirculating eddy flow or oscillating 
pulsatility) caused by curvature or bifurcations in the vessel.43,44  The presence of a permanent 
recirculating eddy in the flow introduces density-dependent centrifugal force, which may alter 
the adhesion profile in these areas.  We investigate this type of disturbed blood flow pattern 
using a modified PPFC setup, in which a vertical step in the channel causes a recirculation eddy 
to form immediately downstream of the step.45  Further down from the step is the a reattachment 
point (a point of flow separation) where a portion of the flow streamline moves downstream 
toward steady laminar flow, and a far downstream region is defined where the flow is 
redeveloped into a steady laminar profile.  We then can observe the particle adhesion profile to a 
layer of inflamed endothelium adjacent to this recirculation eddy, as well as in the far 
downstream region.   
 Figure 5.5 shows the adhesion of targeted PS, Si, and Ti spheres to activated HUVEC 
from blood flow with an imposed recirculation eddy.  At this shear rate (200 s-1, as calculated 
from the expanded section of the chamber), the recirculation eddy is roughly 225 μm from the 
step to the stagnation point (the point at which flow separates).  It is apparent, particularly for Si 
and Ti particles, that adhesion then is a function of distance downstream of the step. Adhesion 
within the recirculation region is increased for Si and Ti particles compared to PS, whether the 
chamber is in the upright or inverted orientation.  The adhesion for Si and Ti spheres is also 
higher than for PS spheres in the far downstream region when the chamber is upright (gravity 
acting in the direction of the HUVEC layer), but there is no significant difference between 
particle types far downstream when the chamber is inverted.  Also, the adhesion of Si and Ti in 
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the recirculating flow pattern and further downstream is not significantly different, suggesting 
that the two particles are redistributed to the wall area about the same. 
 It should be noted that the adhesion in the recirculation channel is not compared directly 
to the laminar flow experiments in Figure 5.1 because those experiments are done at a higher 
shear rate and in a channel with a smaller height.  A separate set of laminar flow assays were 
done at the same shear rate and channel height (200 s-1, 508 µm) as the recirculation flow assay, 
in order to elucidate the effect of the recirculation eddy on adhesion in the far downstream region 
of the channel (Figure 5.6).  In the recirculation region and in the far downstream region in an 
upright channel, adhesion for Si and Ti spheres is roughly twice that of the adhesion in steady 
laminar flow in a straight channel, while PS spheres is about the same regardless of flow type.  
When the chamber is inverted, there is no difference in particle adhesion from laminar flow with 
upstream recirculation and laminar flow in a straight channel. 
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Figure 5.5  Adhesion of sLea-coated PS, Si, and Ti spheres (500 nm ESD) to inflamed 
endothelium after 5 mins of particle-loaded RBC flow (5x105 particles/mL blood) at 200 s-1.  
Experiments were done in a recirculation flow PPFC setup with the endothelial monolayer at the 
bottom (A,B) or top (C,D) of the chamber.  Student t-test were performed comparing particle 
adhesion to *PS and #Si at the same chamber orientation. A p-value < 0.05 was considered 
statistically significant. 
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Figure 5.6  Adhesion of sLea-coated PS, Si, and Ti spheres (500 nm diameter) to inflamed 
endothelium after 5 min of steady laminar particle-loaded (5x105 particles/mL total volume) 
RBC-in-buffer flow at a shear rate of 200 s-1.  The chamber had a height of 508 µm and the 
orientation was varied. 
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 Since the improved adhesion in recirculation flow diminishes in an inverted channel, it 
may be that the negative gravity component overrides the benefit of the recirculation eddy.  
Then, it is of interest to examine whether the adhesion in the inverted channel will improve if the 
magnitude of the centrifugal force is increased.  To test this we examined the adhesion of PS, Si, 
and Ti particles from recirculation blood flow at a higher shear rate of 625 s-1.  Indeed, we find 
that at this higher shear rate, the Si spheres appear to be less sensitive to gravity force due to the 
chamber being inverted compared to at 200 s-1 (Figure 5.7).  Inverted the chamber at 200 s-1 
results in a 55% and 68% decrease in binding of Si spheres in the disturbed region and far 
downstream, respectively, compared to the upright chamber.  At 625 s-1, these decreases in Si 
adhesion are only 25% and 28%, suggesting that the increased shear makes adhesion less 
dependent on chamber orientation.  The PS particles which are essentially neutrally-buoyant 
show no dependence on chamber orientation, while the Ti particles only show decreased binding 
in the far downstream region of the inverted chamber.   
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Figure 5.7  Adhesion of sLea-coated PS, Si, and Ti spheres (500 nm diameter) to inflamed 
endothelium after 5 minutes of particle-loaded RBC flow (5x105 particles/mL total volume) at 
625 s-1. Experiments were done in a recirculation flow PPFC setup with the endothelial layer at 
the bottom (A,B) or top (C,D) of the chamber.  A Student t-test was used to compare particle 
adhesion to *PS adhesion at the same chamber orientation. A p-value < 0.05 was considered 
statistically significant. 
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5.3 Discussion 
 The design of vascular targeted carriers (VTCs) has garnered significant attention recent 
years because of the potential to achieve highly localized delivery to diseased tissues.  It has 
become clear that the physical parameters, such as particle size and shape, are important in 
determining the ability of VTC to marginate and adhere to the vascular wall from blood flow.1–
3,5–7,46,47 In light of the wide variety of carrier types proposed, particle density is a relevant 
parameter to explore for its potential effects on margination and adhesion.  Particle density has 
been shown in simple buffer flow to affect margination40, however it remains unclear how 
particle density affects margination in blood flow.  Sub-micron sized particles which are 
neutrally buoyant have been shown to marginate inefficiently in the presence of RBCs, making 
them sub-optimal as VTCs.1–3,5–7,46,47  In this work, we attempt to directly compare the 
margination in blood and adhesion to HUVEC of neutrally buoyant particles with particles that 
are twice and four times as dense to determine the effect density has on targeting.   
 The results of this study show that despite having the same coating of targeting ligands, 
particles of different density display differences in targeting ability in buffer flow and 
particularly in the presence of RBCs.  The fact that we see adhesion increase with particle 
density in pure buffer flow is an initial indication that gravity may play a role in particle 
margination at this particle size. This is in contrast to a previous study which showed that in 
buffer flow, increased density had a negative effect on margination of nanospheres with 
diameters ranging from 60-65 nanometers.40 However, these contrasting results are potentially 
due to the different particle sizes used for experiments.  The gravity component for the 65 nm 
spheres is neglected and the decreased margination is attributed to the increased particle 
momentum competing with Brownian motion toward the chamber wall.  The 500 nm 
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nanospheres used here will have a larger gravity force, which could contribute to their 
margination to the bottom of the chamber compared to the smaller (60-65 nm) nanospheres 
rather than being negligible.   
 The addition of RBCs results in the increased adhesion of each particle type compared to 
buffer, which is not surprising, as RBCs are known to improve adhesion kinetics for 
cells/particles by providing an additional force normal to the endothelium which helps counteract 
the shear force imparted by blood flow that would act to remove adherent cells from the 
surface.48  What we find here, however, is that this RBC effect on adhesion is not the same for 
particles with different densities, as Si spheres display significantly greater adhesion than either 
PS or Ti spheres, despite Ti spheres displaying the greatest adhesion in buffer flow.  One 
possibility for this increased adhesion is a difference in the number of particles localized to 
channel wall, providing more particles an opportunity to bind.  Indeed, Si spheres on average 
localized close to the wall in higher amounts than either PS or Ti spheres (though differences 
were not significantly different).  Also, the addition of RBCs elicited increased localization of Si 
spheres compared to in buffer flow, while RBCs actually decreased the localization of both PS 
and Ti spheres.  Overall, the combination of improved localization along with the RBC-aided 
adhesion potentially explains why the Si spheres in Figure 5.1B exhibited disproportionately 
higher adhesion than both PS and Ti spheres.  It is known that parameters such as shape, size, 
and membrane rigidity can affect induced migration of particles/cells in blood; and we see here 
evidence that density may play a role as well.  The question that remains is why are Ti particles 
exhibiting lower localization (and hence lower adhesion) than Si particles despite their 
significantly higher density?  Recent reports by Kumar and Graham show that heterogeneous 
collisions between deformable RBCs and more rigid cells and particles contributes to the 
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margination of such cells/particles to the CFL, where the rigid particles experience a substantial 
displacement upon collision with the larger deformable RBCs.49–51  It is possible that density 
neutral and slightly dense particles such as PS and Si are easily displaced in this manner with the 
latter of the two experiencing a greater displacement due to larger momentum.  However, the Ti 
particles (which are 4 times as dense) may require larger force from RBC impact to displace it 
from its original trajectory. 
 Another possibility is the presence of inertial lift forces acting on particles within 
microchannel flow.  It is well described that even in parallel plate microchannels with relatively 
low Reynolds numbers, inertial lift forces arising from the parabolic flow profile (as is present in 
our setup) can result in the lateral migration of particles across streamlines.52  We suspect that 
these forces may be at play in our setup, though the situation is made more complex by the 
presence of RBCs.  An estimate of the migration velocity of a particle away from the center of 
flow can be made using the Equation 5.1:53  
Equation 5.1   Particle migration velocity due to inertial lift force. 
𝑈𝑃 = 𝜌𝑈𝑚2 𝑎33𝜋𝜋𝐷ℎ2 𝑓𝑐 
where 𝑈𝑃  is the particle migration velocity, 𝜌  is fluid density, 𝑈𝑚  is the maximum channel 
velocity, 𝑎 is the particle diameter, 𝜋 is fluid viscosity, 𝐷ℎ is the hydraulic diameter, and 𝑓𝑐 is a 
lift coefficient which can be assumed ~0.5 for flow through parallel plates.53  Using Equation 5.1 
and assuming particles in simple buffer flow in our flow chamber at a WSR of 500 s-1, the lateral 
migration velocity should be on the order of nanometers/sec which seems negligible, however if 
occurring within the CFL could potentially result in migrations toward the endothelium. Also 
acting on the particles is a wall induced lift force that acts to push particles away from the wall 
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when the particle is sufficiently close.  Therefore particle motion in the CFL may be governed by 
a combination on inertial and wall lift force, gravity forces, momentum, and collisions with 
RBCs acting to keep particles in the CFL. The particle Reynolds number is a metric that can 
indicate the importance of inertial lift forces in determining particle behavior, which is calculated 
using Equation 5.2, where 𝜈 is the fluid kinematic viscosity. 
Equation 5.2  Particle Reynolds number in flow chamber setup 
𝑅𝑝 = 𝑈𝑚𝑎2𝜈𝐷ℎ  
Particle motion is dominated by inertial lift when the particle Reynolds number is on the order of 
1, however in our setup the particle Reynolds number is much less than 1 (as is the case with 
nanoparticle flow in most microscale channels) suggesting that inertial lift forces may be 
negligible in this setup53.  The Stokes number is a metric which will indicate the propensity of 
particles to move across streamlines, as it compares particle inertia with viscous dissipation via 
the fluid. The Stokes number is calculated for our situation using Equation 5.3, where 𝜌𝑝 is the 
particle density and 𝑈 is the average velocity of the flow.54 
Equation 5.3  Stokes number of particle in microchannel flow 
𝑆𝑆 =  𝜌𝑝𝑎2𝑈18𝜋𝐷ℎ 
As particles with different density will have different Stokes numbers, and thus different 
propensities to move across streamlines, it is possible that particles will have different tendencies 
to collide with the endothelium once in the CFL (though the Stokes numbers calculated within 
our channel are still < 1 indicating a propensity to follow streamlines).  Overall, it seems the 
major difference causing differences in adhesion lies with the interactions with RBCs causing 
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different localization levels to the CFL, while differences in motion once in the CFL may 
provide an additional impact on the adhesion efficacy. 
 Another factor to consider is the fact that particles with different density will carry 
different translational momentum which could affect the ligand/receptor adhesion.  We know 
from previous works that there exists a “critical shear rate” (CSR), above which the resulting 
particle adhesion decreases with increasing shear rate – due to transition of particle binding into 
a reaction-limited regime.3  This CSR is highly dependent on particle diameter, as increasing 
particle size increases the shear removal force felt by a particle in blood flow.  For a given 
particle size, there is a shear rate above which adhesion is limited by the adhesion kinetics being 
overwhelmed by the shear removal forces.  We see evidence in this work that this CSR may be 
density-dependent as well.  This makes sense, as at a given shear rate and ligand surface 
coverage, a Ti particle would need to overcome a higher force than a Si particle to firmly adhere.  
We do see that the adhesion efficiency for both particle types was found to consistently decrease 
with increasing shear rate, which is likely because of the corresponding increase in translational 
momentum competing with adhesion forces.  Ti particles may be more susceptible to this 
phenomenon than Si spheres, resulting in the observed difference in apparent CSR.  This 
difference in the adhesion profile for particles with different density is an interesting observation, 
particularly when considering that the vasculature contains a wide range of local shear rates and 
blood flow profiles. Thus, it may well be that the optimal targeting of specific areas of the 
vasculature requires a particle type with a specific density, depending on the local 
hemodynamics and blood flow profile.  It is also important to note that the apparent CSRs 
observed in this study are specific to the experimental protocol used, and that CSR could change 
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based on experimental variables that could affect the hemodynamics or reaction kinetics such as 
targeting ligand density, channel height, hematocrit, flow profile, etc. 
 The addition of centrifugal force via an induced recirculation eddy had noticeable effects 
on non-neutrally buoyant particles as well, particularly within the disturbed flow region in the 
immediate vicinity of the recirculation eddy. In a previous work, we use this setup to examine 
the adhesion pattern of neutrally-buoyant spheres and rods and found no improvement due to 
shape within the recirculation region (Chapter 3).7  Interestingly, we do see increased adhesion in 
this region due to density of these particles.  This increase in adhesion is most pronounced when 
gravity is also acting on the particles in the direction of the HUVEC monolayer.  The fact that we 
still see higher adhesion of Si and Ti particles compared to PS in the disturbed region with 
gravity opposite the direction of the HUVEC suggests that the presence of the recirculation eddy 
is causing increased redistribution of Si and Ti particles to the CFL and thus the HUVEC 
monolayer.  This observation is further supported by the observation that non-neutrally buoyant 
particles exhibit increased adhesion in the recirculation flow compared to laminar flow 
(comparing Figure 5.5 to Figure 5.6).  In an inverted channel, this effect is diminished in the far 
downstream region – showing that gravity effects still persist.  By increasing the shear rate 
(Figure 5.7), thus increasing the contribution due to centrifugal force, we find the adhesion of Si 
spheres is significantly less dependent on chamber orientation. The results in this study suggest 
that the combination of particle density-dependent gravity and centrifugal forces can both affect 
localization and subsequent adhesion to the endothelium depending on local hemodynamics, 
which vary drastically depending on which area of the vasculature is targeted.   
 This study shows evidence that particle density may be a useful parameter for optimizing 
the performance of vascular-targeted carriers.  In this study the densities investigated range from 
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1.05 - 3.9 g/cm3, however the density range of proposed drug carriers is even wider.  Buoyant 
microbubbles as well as high density metal based particles including iron oxide (~5 g/cm3) and 
gold (~19 g/cm3).  The wide range of particle densities along with tunable particle shape, size, 
and surface properties provides a vast parameter space which can be explored to improve site 
specific targeting. 
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CHAPTER 6: IN VIVO TARGETING AND BIODISTRIBUTION OF 
TARGETED SUB-MICRON SPHERES OF DIFFERENT MATERIAL 
AND DENSITY 
 
 
ABSTRACT 
 
 We have seen in vitro that particle density, as with particle size and shape, can affect the 
margination and adhesion of vascular-targeted carriers in the presence of red blood cells.  
Naturally, it is of interest whether these effects will translate to better targeting ability in the 
more complex in vivo environment, which will include interactions with blood plasma, white 
blood cells, and platelets.  Also, the hemodynamic conditions throughout the vasculature vary 
dramatically, which may affect the areas in which particles of different density are best suited for 
targeting.  In this study, vascular-targeted PS, Si, and Ti spheres with 500 nm diameter are 
administered to mice with systemic inflammation; and the ability to target inflamed aorta is 
compared.  Also, biodistribution studies are performed to determine in which major organs the 
targeted or non-targeted particles tend to accumulate.  We find that on average, Si spheres adhere 
to inflamed aorta at higher levels than either PS or Ti spheres.  Specifically, we find Si (and in 
some regions Ti) spheres bound at significantly higher levels compared to PS at upper segments 
of the aorta including the aortic arch, brachiocephalic artery, left common carotid artery – areas 
characterized by complex hemodynamics and known to be prone to atherosclerosis.  
119 
 
Further down the aorta, we find similar adhesion of PS and Si spheres while Ti sphere adhesion 
was minimal.  Non-targeted control particles displayed no adhesion to the aorta, demonstrating 
the targeting specificity of the ligands used.  Non-targeted and targeted particles of all types 
accumulated in significant amounts in the liver and spleen, while only targeted particles 
displayed significant accumulation in the lungs – consistent with targeting to systemic 
inflammation. 
 
120 
 
6.1 Introduction 
 A wide variety of material types are proposed for use as vascular targeted carriers.  As 
such, it is of interest to investigate how different carrier types behave in vivo due to their physical 
characteristics.  We have shown in vitro that particle density may have an effect on overall 
targeting ability due to density-dependent forces in flow and particle/RBC interactions.  It is then 
of interest as to whether these effects will remain evident in a more complex physiological 
environment.  In addition to interacting with RBCs, particles in vivo are also be subject to 
opsonization of plasma proteins, interactions with circulating phagocytes, and innate filtration 
mechanisms which would remove foreign particles from circulation.1–6  Also, the local 
hemodynamics vary drastically throughout the vasculature.7 The vessel diameter, vessel 
branching, local shear rate, hematocrit, and flow type (steady, pulsatile, oscillating) can be quite 
different depending on which area of the vasculature is being targeted, and these parameters all 
have been shown to have effects on the ability of particles to adhere to endothelium.   
 Many different types of vascular-targeted vehicles for drug delivery or imaging have 
been tested for their efficacy in targeting diseased tissue in vivo, including microbubbles8–10, 
liposomes11–13, polymer nanoparticles14–16, dendrimers17–19, and inorganic nanoparticles20,21.  
Often, studies have compared the targeting ability of vascular-targeted particles to non-targeted 
control particles, displaying the efficacy of the targeting system; or have compared the efficacy 
of drug-loaded particle administration to that of free-drug administration to show improved 
treatment with targeted drug-loaded particles.  Polymeric and inorganic particles have been 
tested in vascular-targeting studies in vivo22–27; however to our knowledge, no studies have been 
done to compare how these particles target and biodistribute with focus on different particle 
density.  We have shown previously that PS spheres with 500 nm diameters do not adhere as 
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efficiently as microparticles in a mouse model of atherosclerosis15,28 following the same trend 
observed for the same particles binding in vitro in human blood29–31.  In this study, we 
investigate whether more dense particles are more effective at adhering to inflamed aorta 
compared to PS spheres, which have density very close to that of blood.  Using a mouse model 
of systemic inflammation, polystyrene (PS), silica (Si), and titania (Ti) particles dual-targeted to 
E-selectin and VCAM-1 are administered to compare directly the ability of particles having 
different densities to target inflammation in vivo.  Specifically we look for differences in 
adhesion along sections of the aorta, as well as biodistribution in major organs.  
6.2 Results 
 Vascular-targeted PS, Si and Ti nanospheres were prepared and injected into wild-type 
male mice at 20 weeks of age as previously described.15,28  Briefly, targeted particles are surface 
coated with sLea and anti-VCAM-1 to target E-selectin and VCAM-1, respectively, and non-
targeted control particles are coated with a non-specific isotype control antibody. Wild-type mice 
are pre-treated with TNF-α for 24 hours to induce systemic inflammation.  Particles are then 
administered via tail-vein injection and allowed to circulate for 30 min before mice are 
sacrificed.  The aorta is isolated and imaged to quantify the adhesion density along each section 
of the aorta.  Also, the lung, liver, spleen, and kidney are harvested to quantify biodistribution in 
major organs. 
6.2.1 Particle Adhesion to Inflamed Mouse Aorta 
 Figure 6.1 shows the adhesion level of dual-targeted PS, Si, and Ti spheres to whole mice 
aortae.  Similar to the trends seen in the in vitro assays, Si spheres adhered to whole mouse 
aortae at significantly higher levels than PS spheres. The adhesion of Ti and PS spheres were not 
significantly different, despite the Ti spheres displaying enhanced adhesion compared to PS 
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under certain conditions in vitro.  Spheres coated with an isotype control antibody did not adhere 
at any appreciable level for all particle types investigated, displaying the targeting specificity of 
the ligands used.   
 Figure 6.2 shows the adhesion normalized to the area of various sections of the aorta, and 
Figure 6.3 shows the overall particle adhesion (not normalized) to each section of the aorta.   The 
adhesion pattern for the different particles varies along different sections of the aortic tree. Si 
spheres display significantly greater adhesion density (normalized to the area of each section) 
than PS spheres particularly in the “upper” segments of the aorta.  The aortic arch and first major 
branchings, including the brachiocephalic artery (and subsequent right common carotid and right 
subclavian) and left common carotid artery, which are known to be particularly prone to 
atherosclerosis28, all display significantly more adhesion of Si particles than PS.  The thoracic 
aorta and abdominal branches also display higher Si binding, while in the “lower” segments of 
the descending aorta ending with the iliac branches, the PS and Si adhesion are not different and 
the adhesion of Ti was significantly lower.  On average, we see a higher normalized adhesion for 
PS and Si spheres near the aortic bifurcation and iliac arteries at the terminal end of the aorta 
compared to the ascending aorta and the thoracic and abdominal segments of the descending 
aorta. 
123 
 
 
Figure 6.1  Adhesion of dual-targeted or isotype control PS, Si and Ti spheres to the inflamed 
aorta of wild-type mice pretreated with TNF-α cytokine for 24 hours.  Particles were injected via 
tail-vein (4x107 particles/mouse) and allowed to circulate for 30 mins.  One-way ANOVA with 
Bonferroni post-test was used to compare particle adhesion to *PS adhesion at the same chamber 
orientation. A p-value < 0.05 was considered statistically significant. 
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Figure 6.2  Normalized adhesion density of dual-targeted or isotype control PS, Si and Ti spheres 
to each section of the inflamed aorta of wild-type mice pretreated with TNF-α cytokine for 24 
hours.  Particles were injected via tail-vein (4x107 particles/mouse) and allowed to circulate for 
30 mins.  One-way ANOVA with Bonferroni post-test was used to compare particle adhesion to 
*PS adhesion at the same chamber orientation. A p-value < 0.05 was considered statistically 
significant. 
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Figure 6.3  Average particle adhesion of dual-targeted or isotype control PS, Si and Ti spheres to 
each section of the inflamed aorta of wild-type mice pretreated with TNF-α cytokine for 24 
hours.  Particles were injected via tail-vein (4x107 particles/mouse) and allowed to circulate for 
30 mins.  One-way ANOVA with Bonferroni post-test was used to compare particle adhesion to 
*PS adhesion at the same chamber orientation. A p-value < 0.05 was considered statistically 
significant. 
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6.2.2 Particle Biodistribution in Major Organs 
 Figure 6.4 and Figure 6.5 show the biodistribution of targeted and non-targeted PS, Si, 
and Ti spheres to major organs (lung, kidney, spleen and liver) in inflamed wild-type mice.  We 
find that presence of targeting ligands on the particles results in increased accumulation of all 
particle types in the lungs compared to the isotype control, likely due to molecular interaction of 
the targeted particles with inflamed endothelium in the lung microvasculature.  Both targeted and 
non-targeted particles displayed minimal accumulation in the kidney, which is expected since 
these particles are larger than what is typically removed from the blood via glomerular filtration.  
The spleen and liver predictably show significant particle accumulation.  Targeted Si spheres 
accumulated less in the spleen and liver than non-targeted Si, however, this specific trend is not 
apparent for PS or Ti particles.  Still, we find in the absence of targeting molecules, the majority 
of each of the particles end up in organs of the RES (liver and spleen).   
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Figure 6.4  Accumulation in major organs of dual-targeted PS, Si, and Ti particles with 500 nm 
ESD.  Accumulation is plotted as % injected dose per gram organ.  
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Figure 6.5  Accumulation in major organs of isotype control IgG coated PS, Si, and Ti particles 
with 500 nm ESD.  Accumulation is plotted as % injected dose per gram organ. 
  
129 
 
6.3 Discussion 
 The adhesion trends seen in the in vitro assays shown in Chapter 5 translated reasonably 
well to the in vivo environment, as Si spheres adhered to inflamed mouse aorta at higher levels 
than either PS or Ti spheres.  The differences in the adhesion patterns of particles along the aorta 
are potentially linked to the hemodynamic conditions and vessel diameter in each section. For 
instance, dense particles displayed greater adhesion in the upper segments of the aorta with high 
curvature and shear rates, potentially aided by additional centrifugal forces improving particle 
margination as was seen in in vitro recirculation assays.  Neutrally-buoyant PS particles display 
low binding density in this area, unaffected by density-dependent forces and less likely to bind in 
a vessel with large diameter and high peak shear.    However, we do see a higher normalized 
adhesion for PS and Si spheres near the terminal end of the aorta compared to in the upper 
segments of the aorta (a result that has been observed previously for PS spheres)32.  It is possible 
that particles of this size are more likely to adhere in the lower aorta sections where the vessel 
diameters are smaller and peak shear rates are lower, resulting result in the observed increase in 
adhesion near the iliacs.7,32 Aside from in the brachiocephalic (and subsequent right carotid and 
subclavian artery) and left common carotid sections, we see minimal adhesion of Ti spheres 
throughout the rest of the aorta.  It is possible that Ti spheres have difficulty adhering in areas of 
the aorta characterized by more continuous laminar shear, while still able to bind in the two 
sections where high vessel curvature is present.  Also there is the possibility that plasma protein 
absorption may negatively affect Ti particle adhesion, as particles of different material may 
attract different types/amounts of plasma proteins.33 
 The observed accumulation of targeted particles in the lung is unsurprising, as 
inflammation will also be present on lung endothelium as well as the aorta.  Also, the lungs are 
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the site of the highest density of capillaries within the vasculature, providing a large area for 
particle adhesion in vessels which are favorable for adhesion.  The results shown here follow 
previous research which also shows the enhanced accumulation of inflammation-targeting 
particles in the lungs when systemic inflammation is present.15,34 Without the presence of the 
targeting ligand, the particles show minimal accumulation in the lung, as they are small enough 
to navigate the capillary beds without mechanical entrapment. 
Regardless of particle type or surface coating, a large portion of the dosage ends up in 
organs of the RES (liver and spleen).  Similar results have been shown in vivo for similar 
particles made from the same materials used in this study.6,35–43  We see clearly that targeted Si 
spheres accumulated less in the spleen and liver than non-targeted Si, likely due to the increased 
adhesion on the aorta, in the lung, and elsewhere in the vasculature. However, it is unclear why 
this trend is not apparent for PS or Ti spheres.  A previous work shows that silica and titania 
particles show distinct differences in the plasma protein corona that forms when introduced to 
plasma despite displaying similar surface charge/zeta potential.33 Since specific opsonins are 
known to affect biodistribution and may enhance/diminish uptake by organs of the RES, it is 
possible that the different particle types may attract protein coronas with enough variation to 
shift the biodistribution profiles, despite the particle surfaces being saturated with the same 
ligands.6 Still, the biodistribution of non-targeted Ti particles follows what was previous shown 
for titania particles of comparable size injected into rats36 and mice35, where the majority of the 
dose is retained in the liver, followed by the spleen, lung, and kidney.   
 Overall, the presented in vivo data also suggests with a better understanding of the local 
hemodynamics in vivo at a specific target site and the implications of material type on 
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biodistribution, there is opportunity to use carrier density and material type as tools for 
improving disease targeting specificity. 
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 Conclusions 
Improving and optimizing the design of vascular-targeted carriers is important as this 
technology moves forward toward widespread clinical use.  Physical characteristics including 
size, shape, density, surface coating, rigidity, etc. must all be considered, as each can potentially 
be a tool for improving targeting performance.  In addition, the hemodynamics and vessel 
geometry present in the must be considered, as targeting to various areas throughout the 
vasculature will likely require unique particle types with specific physical characteristics for 
optimal targeting.  In this work we find that particle shape and particle density both can affect the 
performance of VTCs in blood flow.  
In Chapter 3 we find a coupled effect of particle shape and size in determining the 
adhesion efficiency of targeted particles in the presence of RBCs.   We find that within the 
parameter space investigated, particle size remains an important factor in determining particle 
localization and adhesion as, other parameters equal, 2 μm ESD particles display more adhesion 
than 500 nm or 1 μm ESD particles regardless of shape.  However, particle shape can indeed to 
be used to improve adhesion compared to an equivalent spherical particle, given that the particle 
volume and particle aspect ratio are both of sufficient magnitude.  Both rod and disk shaped 
particles with ESD ≥ 1 μm displayed improved adhesion compared to equivalent spheres, though 
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particles 500 nm ESD remain limited by their ability to localize to the CFL in the presence of 
RBCs. 
 In Chapter 4, we find that that the trends observed in Chapter 3 translate to improved 
plaque targeting ability in vivo using a mouse model of atherosclerosis.  The targeting ability of 
500 nm ESD rods and spheres are limited by their size (thus inefficient margination), while 
particles with 2 μm ESD display significantly higher compared to smaller particles.  We find that 
2 μm rods with AR4 adhere to plaques significantly more than equivalent spheres, demonstrating 
their superior utility as a vascular-targeted carrier towards atherosclerosis.  We also find, 
however, that the improved adhesion also translates to increased accumulation of rods in the 
lungs due to systemic inflammation, noting the need for careful choice of specific targeting 
ligands to prevent unwanted delivery away from the target site. 
In Chapter 5, we see that particle density affects the adhesion of nanoparticles (500 nm 
diameter) in both buffer flow and in the presence of RBCs.  Silica spheres, which have a density 
roughly twice that of blood, exhibit improved adhesion to inflamed endothelium compared to 
polystyrene or titania spheres in the presence of RBCs, regardless of the direction in which 
gravity is acting.  Titania spheres (4 times more dense than blood) adhere at levels higher than 
polystyrene, but only in conditions when gravity or centrifugal force acts in the direction of 
adhesion.  As expected, neutrally-buoyant polystyrene spheres appear to be unaffected by 
density-dependent forces.   
In Chapter 6, we find that the results obtained in Chapter 5 translate reasonably well to an 
in vivo mouse model of systemic inflammation.  Overall, silica spheres displayed increased 
adhesion to inflamed aorta compared to polystyrene or titania spheres.  Titania spheres also 
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displayed increased adhesion compared to PS in specific sections of the aorta, while displaying 
significantly less adhesion toward the terminal end of the aorta, potentially related to the 
different hemodynamic conditions present in these areas.  Particles targeted toward inflammation 
display enhanced accumulation in the lungs due to molecular interactions, while a significant 
portion in the targeted and non-targeted dosage accumulates in the spleen and liver.  
In conclusion, we find that along with particle size, particle shape and density are indeed 
parameters which should be considered when designing vascular-targeted carriers.  By 
optimizing the physical characteristics of VTCs, we can improve the treatment and diagnosis of 
many diseases by providing highly localized, highly site-specific delivery.  With a robust 
understanding the effects that physical parameters have on targeting, we may be able to 
eventually provide disease-specific or even patient-specific vascular-targeted carrier systems. 
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7.2 Future Directions 
In light of the results presented in this dissertation and the current state of the field of 
vascular-targeting, there are several areas of interest for further research to help drive the 
improvement of vascular-targeted carriers. 
(1) Explore the vastly wider parameter space in terms of particle shape and density.  
Advancements in fabrication methods provide the ability to produce monodisperse 
populations of a various particle shapes which could produce differences in adhesion 
patterns.  Non-spherical particles with high relatively density, such as gold nanorods 
or carbon nanotubes, can also be investigated since theoretically the lateral drift 
magnitude for such particles should be higher than for neutrally-buoyant particles.  
Direct comparisons between particles of equivalent volume or shape are important to 
determine which physical parameters are most important in prescribing targeting 
efficacy.  
(2) Identify whether the adhesion of differently shaped particles is affected by plasma 
protein interactions.  It is known that surface curvature can elicit different responses 
in terms of plasma protein corona, however, how these differences affect active 
targeting remains unclear.   This may also have implications on the long term fate of 
particles administered in vivo, after the initial margination/adhesion step has occurred. 
(3) Compare the effects of particle size/shape/density for particles with ESD in the range 
of tens of nanometers.  It has been shown that large nanoparticles and sub-micron 
particles can be inhibited by the presence of the RBC core, preventing their 
accumulation in the CFL.  However, by definition, the CFL is a region of highly 
enriched plasma.  Therefore, by using very small particle sizes, it is possible that 
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particles can then behave as soluble molecules, possibly also becoming enriched in 
the CFL region rather than being inhibited by RBC core entrapment. 
(4) Specifically match numerous hemodynamic conditions in vitro to specific sites within 
the in vivo vasculature, in order to assess the extent to which different areas of the 
vasculature will require a carrier with different physical characteristics to result in 
optimal targeting.  In this way we can move toward predetermining what carrier 
design will be ideal for targeting a specific disease or possibly within a specific 
patient. 
(5) Investigate the ability to direct post-adhesion outcome of vascular-targeted carriers on 
a longer time scale.  By using a continuous, closed system experimental setup, an in 
vitro model of the vasculature can be used to identify the ability of targeted carriers to 
persist on the endothelium, become internalized, deliver relevant drug concentrations, 
etc, in the presence of physiological shear.  These in vitro results can then be 
compared to in vivo findings in which the time-dependent outcome of VTC 
administration is investigated. 
 
 
 
 
 
 
